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Here, we present a novel approach for the chemical synthesis of chondroitin and 
dermatan sulfate oligosaccharides. A key point of this strategy is the preparation and 
use of an N-trifluoroacetyl galactosamine building block containing a 4,6-O-di-tert-
butylsilylene group. Glycosylation reactions proceeded in good yields (74-91%) with 
our protecting group distribution. Using this approach, we have synthesized, for the first 
time, a chondroitin/dermatan sulfate-like tetrasaccharide that contains both types of 
uronic acids, D-glucuronic and L-iduronic acid. Moreover, we have employed a 
fluorescence polarization competition assay to evaluate the interactions between the 
synthesized oligosaccharides and FGF-2 (basic Fibroblast Growth Factor). Our results 
show that this method, using standard instrumentation and minimal sample 
consumption, is a powerful tool for the rapid analysis of the glycosaminoglycan affinity 
for proteins in solution. 
Introduction 
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Chondroitin sulfate (CS) and dermatan sulfate (DS) are highly heterogeneous and 
sulfated, linear polysaccharides that belong to the glycosaminoglycan (GAG) family.1, 2 
CS is formed by the repetition of disaccharide units of D-glucuronic acid (GlcA) and N-
acetyl-D-galactosamine (GalNAc), following the sequence GlcA-β(1→3)-GalNAc-
β(1→4). The disaccharide repeating unit of the structurally related DS mainly contains 
L-iduronic acid (IdoA) in place of GlcA. Both polysaccharides may contain sulfate 
groups at different positions of the chain (Figure 1). These sulfate groups are introduced 
during the biosynthesis of these polymers, through the action of specific 
sulfotransferases, giving rise to GAG chains with a high level of structural diversity. 
The microheterogeneity of CS and DS can be considered as a capacity to encode 
information and control a wide variety of biological processes by specific interactions 
with certain proteins.3 As in the case of others members of the GAG family, such as 
heparin and heparan sulfate,4-8 it is proposed that defined CS and DS oligosaccharide 
sequences are responsible for specific protein recognition and subsequent activity.3 
However, little is known about the exact structural requirements for these interactions. 
In this context, synthetic CS and DS oligosaccharides9-13 are useful tools for the 
establishment of structure-activity relationships and the preparation of mimetics that 
potentially modulate the biological functions of the natural products.14-16     
Interestingly, CS and DS are often found as co-polymeric structures.17 These hybrid 
CS/DS chains, containing both types of uronic acids, GlcA and IdoA, are involved in 
growth factor signalling and neuronal growth and development.17 The interaction 
between CS/DS and several chemokines and growth factors, including FGF-2 (basic 
Fibroblast Growth Factor), is mediated by oversulfated oligosaccharide sequences 
containing GlcA/IdoA-GalNAc (4,6-OSO3).
18-21 In order to study these interactions at 
the molecular level, it would be very useful the access to well-defined synthetic CS/DS 
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oligosaccharides. However, to the best of our knowledge, the synthesis of a CS/DS 
oligomer, containing both GlcA and IdoA, has not yet been reported.     
Despite significant advances in the field,22-33 the synthesis of GAG oligosaccharides, 
including DS and CS, is still challenging, mainly due to the low reactivity of the 
building blocks required.34-37 There is still a great demand for efficient synthetic 
strategies, involving a robust and reliable set of carbohydrate building blocks. This is an 
important point for the successful automation of oligosaccharide synthesis.33, 38-40  
Here, we present a novel approach for the synthesis of CS and DS oligomers that is 
based on the use of an N-trifluroacetyl-protected galactosamine building block. 
Glycosylation reactions proceeded in high yields using our design of protecting groups. 
The efficiency of this strategy is illustrated with the total synthesis of the oversulfated 
tetrasaccharide 1 (Scheme 1) that contains both IdoA and GlcA and bears sulfate groups 
at positions 4 and 6 of the GalNAc units, position 2 of the uronic acid moieties, and 
position 4 of the non-reducing terminus. All these positions may be sulfated in the 
natural products (Figure 1), except position 4 of the non-reducing end. Interestingly, the 
introduction of a “non-natural” sulfate group at the reducing end did not significantly 
affect the FGF-2 affinity of a synthetic heparin hexasaccharide41 and an “artificial” 
IdoA monosaccharide, sulfated at positions 2 and 4, showed considerable binding to 
several proteins.42, 43 Moreover, we have developed a fluorescence polarization assay to 
analyse the binding of tetrasaccharide 1 and its di-O-benzylated precursor to a model 
heparin-binding protein, FGF-2. Fluorescence polarization measurements allowed the 
study of GAG oligosaccharide-protein interactions in solution, with minimal time and 
sample consumption, and using a standard fluorescence reader. Therefore, our results 
indicate that this method can be considered as a powerful tool to evaluate the binding 
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affinities of synthetic oligosaccharides for receptors of biological relevance, helping to 
establish structure-activity relationships.            
Results and discussion 
Synthesis of chondroitin/dermatan sulfate-like oligosaccharides 
For the synthesis of the CS/DS-related tetrasaccharide 1, we first prepared the required 
monosaccharide building blocks 2-4 (Scheme 1). Glucuronic acid trichloroacetimidate 2 
was prepared from known diol 5,44 as shown in Scheme 2. Selective oxidation at 
position 6 was performed by treatment of the diol 5 with calcium hypochlorite and 
catalytic TEMPO, under phase-transfer conditions.44 Strict control of the reaction time 
and temperature, and quenching with Na2SO3 were required to avoid the chlorination of 
the electron-rich 4-methoxyphenyl ring.45 The carboxylate intermediate was then 
esterified with BnBr and Bu4NI in DMF at 60ºC to give the benzyl uronate 6. 
Levulinoylation at position 4, followed by oxidative removal of the 4-methoxyphenyl 
group with CAN, and trichloroacetimidate formation, afforded glycosyl donor 2. 
Starting from diol 9,46, 47 iduronic acid trichloroacetimidate 3 was obtained by 
levulinoylation, selective desilylation and anomeric activation with Cl3CCN and K2CO3.  
Regarding the galactosamine unit, two types of building blocks, possessing different 
protections on the amino group, have been employed, up to date, for the synthesis of CS 
and DS oligosaccharides.10 2-Azido-2-deoxy-galactose derivatives11, 12, 48-51 present 
some limitations for their general use due to the non-participating character of the azido 
moiety. On the contrary, 2-deoxy-2-trichloroacetamido-galactose building blocks lead 
to the stereoselective formation of the required 1,2-trans glycosidic bond. Impressive 
synthesis of CS oligomers have been reported using N-trichloroacetyl(TCA)-protected 
units.3, 32, 52-55 However, this amino protecting group is associated with some problems. 
For example, we56 and others57 have detected the formation of stable trichlorooxazoline 
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side products during glycosidation of 2-deoxy-2-trichloroacetamido donors. Moreover, 
several difficulties are occasionally encountered in the final transformation to the 
desired 2-acetamido group. Thus, the deprotection of multiple N-TCA groups by basic 
hydrolysis, followed by selective N-acetylation, requires very long reaction times.57 
Alternatively, radical reduction using tributylstannane afford, in some cases, significant 
amounts of mono- and dichloroacetamide intermediates.58, 59 For these reasons, we 
considered the use of an alternative amine-protecting group for the synthesis of CS/DS 
oligosaccharides. We chose an N-trifluoroacetyl (TFA) group because it can be easily 
removed under mild conditions while ensures high β selectivities in glycosylation 
reactions.60 
Thus, we first planned the preparation of a N-TFA-protected galactosamine unit that 
should act as an efficient glycosyl acceptor in coupling reactions with uronic acid 
donors. The synthesis of such a compound was challenging (Scheme 3). Known 
tetraacetate 1261, 62 was synthesized from galactosamine hydrochloride in 66% yield by 
treatment with NaOMe and then with trifluoroacetic anhydride and Et3N in MeOH, 
followed by extensive acetylation (Ac2O, Py, DMAP). Compound 12 was transformed 
into 4-methoxyphenyl glycoside 15 by glycosylation with 4-methoxyphenol, followed 
by de-O-acetylation and benzylidenation. This compound was an ideal candidate for our 
synthetic approach because the 4,6-O-benzylidene acetal would allow the selective 
sulfation of these positions at the end of the synthesis to generate, among others, 
biologically relevant type E sulfation sequences.3 However, 15 suffered from poor 
solubility in organic solvents such as dichloromethane, toluene and acetonitrile, and 
glycosylation attempts with uronic acid donor 263 in THF or THF/CH2Cl2 mixtures did 
not give any desired disaccharide. We then decided to prepare compound 17 with a silyl 
ether group at the anomeric position. Selective cleavage of the anomeric acetyl group of 
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12 was followed by treatment with TDSCl to afford derivative 16. Acetate hydrolysis 
and benzylidenation gave compound 17. Surprisingly, this derivative proved to be 
unstable during silica gel chromatography. Therefore, 17 was not considered anymore 
as building block for our synthetic scheme. We then directed our attention to the 6-O-
chloroacetylated building block 18, efficiently synthetized from 16 in two steps. It was 
anticipated that diol 18 would be selectively glycosylated at position 3. Unfortunately, 
glycosylation reactions between diol 18 and uronic acid donor 263 proceeded in low 
yield (<15%) and regioselectivity. Finally, we decided to prepare monosaccharide 4 
containing a di-tert-butylsilylene group. It has been reported that this protecting group, 
compared to benzylidene acetals, confers desirable properties to glycosyl acceptors, 
such as better solubility in most organic solvents and higher stability under acidic 
glycosylation conditions.58, 64 Thus, we treated monosaccharide 14 with di-tert-
butylsilyl bistriflate in pyridine to obtain 4 in high yield. Gratifyingly, coupling of 4 
with glucuronic acid trichloroacetimidate 2 gave the desired β (1→3) disaccharide 19 in 
excellent yield (Scheme 4). These results highlight the profound effect that protecting 
group distribution of the building blocks has on glycosylation reactions.65 We also 
perfomed the glycosylation reaction between 4 and iduronic acid donor 3. The target α 
(1→3) disaccharide 20 was also obtained in high yield. The small-to-zero coupling 
constants for IdoA protons indicated that this residue mainly exists in 1C4 conformation, 
and the value of the 1JC, H (172 Hz) confirmed the α configuration of the new glycosidic 
linkage.66  
Next, we studied the 2+2 assembly of the disaccharide units 19 and 20 to generate a 
tetrasaccharide sequence containing both GlcA and IdoA. The 4,6-di-tert-butylsilylene 
group67 of galactose and galactosamine donors leads to the selective formation of α 
glycosides despite the presence of participating groups at position 2.68 In some cases, 
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even 4,6-O-benzylidene derivatives of galactosamine donors may lead to loss of 
stereocontrol in coupling reactions with glucuronic acid-derived acceptors.69 For these 
reasons, we decided to transform disaccharide 20 in a suitable protected donor 
containing less sterically hindered acetyl groups at positions 4 and 6 to obtain the 
desired 1,2-trans glycoside with excellent stereoselectivity. Cleavage of the silylene 
group gave diol 21. The isolation of this compound was tricky because 21 formed gels 
in several solvents, such as toluene, CH2Cl2 and EtOAc. Therefore, diol 21 was directly 
acetylated, without further purification, to yield compound 22. Removal of the 4-
methoxyphenyl group followed by treatment with Cl3CCN and catalytic DBU gave 
donor 24. On the other hand, 19 was transformed into acceptor 25 by treatment with 
hydrazine monohydrate in a pyridine/acetic acid solution. Coupling of disaccharides 24 
and 25 gave the target β tetrasaccharide 26 in high yield. This result demonstrates the 
utility of our synthetic route for the assembly of CS and DS oligosaccharides, paving 
the way for other sequences with different sulfation patterns.  
Tetrasaccharide 26 was submitted to the deprotection/sulfation steps to obtain final 
compound 1. Cleavage of the silylene group was performed by treatment with (HF)n·Py 
complex. Hydrolysis of the acyl groups, benzyl and methyl esters, and 
trifluoroacetamides was carried out by treatment with lithium hydroperoxide and then 
NaOH to give compound 28. The amine groups were selectively acetylated with Ac2O 
in MeOH to provide intermediate 29, which was purified by gel permeation 
chromatography. Then, extensive O-sulfation using SO3·Me3N in DMF at 100 °C under 
microwave heating41, 70 gave cleanly the corresponding hepta-O-sulfated tetrasaccharide 
30, which proved to be soluble in water. This compound was converted into the 
corresponding calcium salt for NMR characterization because the 1H-NMR spectrum of 
the sodium salt showed considerable signal overlap. NMR spectra showed the 
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characteristic downfield shifts of the proton and carbon signals at positions bearing a 
sulfate group (see Table 1 and 2). COSY, HSQC and TOCSY NMR experiments were 
employed for the structural assignment. Additionally, mass spectroscopic analysis 
confirmed the structure of 30. Finally, hydrogenolysis of 30 gave the fully deprotected 
tetrasaccharide 1 in good yield. The structure of 1 was confirmed by NMR and mass 
spectroscopic analysis. The values of 1H and 13C NMR chemical shifts for sulfated 
positions are in good agreement with those reported in the literature for similar GAG 
sulfated sequences.41,53                                    
Fluorescence polarization measurements 
Fluorescent polarization is a powerful tool for the study of biomolecular interactions in 
solution.71 It is based on the observation that when a fluorescent molecule is excited 
with plane-polarized light, the remaining polarization of the emitted light depends on 
the rotational rate of the fluorescent molecule in solution that is inversely related to its 
molecular weight. Thus, the light emitted by a small fluorescent compound, which 
rotates quickly in solution, is highly depolarized and, therefore, the polarization value is 
low. If the fluorescent probe binds to a high molecular weight molecule, for example, a 
protein, the large complex rotates slower in solution, the emitted light remains 
polarized, and the polarization value is higher. Importantly, fluorescence polarization 
measurements do not require immobilization of protein or ligand to a surface for the 
analysis of the interaction. Thus, ligand’s bound/free ratio can be directly measured in 
solution, avoiding potential misleading effects derived from the attachment of the 
biomolecules to solid supports. Moreover, this technique is adequate for high 
throughput screening, requires very little amount of samples, and is well suited for the 
binding analysis of small ligands, such as oligosaccharides, to a protein receptor. 
Despite these advantages, fluorescence polarization has had a limited use in the study of 
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carbohydrate-protein interactions,72, 73 in part due to the lack of sensitive and appropiate 
instrumentation until the late 90’s. Interestingly, competition assays can be easily 
designed to study the binding affinities of nonfluorescent ligands.72 In fact, we 
employed a competition experiment to evaluate the affinity of synthetic tetrasaccharides 
1 and 30 to FGF-2, as described below. 
First, we prepared five different fluorescein-conjugated glycosaminoglycan 
oligosaccharides (36-40) to select an optimal probe for binding studies with FGF-2 
(Scheme 7 and Supplementary information). Commercially available oligosaccharides 
31-35, derived from natural heparin by enzymatic depolimerization, were functionalized 
by reaction of the aldehyde group of the reducing end of the chain with a hydrazide-
containing fluorescein molecule.74 The corresponding glycosyl hydrazides were 
obtained in good yield, after purification by reverse phase C-18 chromatography. Then, 
fluorescent labelled sugars 36-40 were mixed with a fixed concentration of FGF-2, and 
polarization was measured in 384-well microplates using a standard fluorescence 
microplate reader (Figure 2). Control wells containing only the fluorescent probe, 
without any protein, were included in the experiment. As expected,75, 76 heparin 
hexasaccharide 38 and tetrasaccharide 37 bound to FGF-2 since a significant increased 
polarization value was observed in FGF-2 containing wells. No interaction was detected 
for heparin disaccharide 36 and hyaluronic acid oligosaccharides 39 and 40, ruling out 
any binding of FGF-2 to the fluorescein tag. Hexa 38, which gave best binding, was 
chosen as optimal probe for inhibition experiments (see below). Importantly, the use of 
384-well plates allowed the minimization of the sample quantities required for these 
experiments: the standard assay was performed with 10 nM fluorescent probe and 
approximately 100 nM protein in a final volume of 40 µL per well. 
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Next, the binding of 38 to FGF-2 was measured with increasing concentrations of 
protein (see Supplementary information, Figure S1), giving the corresponding binding 
curve that was analyzed as a Langmuir isotherm to determine the dissociation constant 
(KD). The obtained value (117 ± 10 nM) was consistent with a previous measurement, 
in solution, of the binding affinity between a similar heparin hexasaccharide and FGF-
2.75 
A competition binding assay was then optimized to analyze the binding affinites of non-
fluorescent ligands, such as tetrasaccharides 1 and 30, to FGF-2. Thus, the polarization 
of samples containing fixed concentrations of protein and fluorescent probe were 
recorded in the presence of a certain concentration of potential competitors (Figure 3). 
In these experiments, we chose an FGF-2 concentration close to the KD of the 
interaction with 38 in order to get a high enough polarization value while still using the 
minimal amount of inhibitor. Besides 1 and 30, synthetic oligosaccharides 41-4641, 77 
were included in the screening (Figure 4). The displacement of fluorescent 38 by an 
active competitor resulted in a decrease of the polarization value (Figures 3 and 4). In 
this way, the inhibitory capacity of non labelled compounds could be easily and quickly 
screened. As shown in Figure 4, at 25 µM concentration, monosaccharide 41 and 
disaccharides 42 and 46 did not significantly affect the interaction between fluorescent 
38 and FGF-2, while hexasaccharides 44 and 45 strongly inhibited the binding. 
Interestingly, the presence of 25 µM of 1 and 30 gave 63-67 % inhibition. A similar 
effect was observed with tetrasaccharide 43. These results indicated that CS/DS-related 
tetrasaccharides 1 and 30 are able to interact with FGF-2 and that their relative 
inhibitory potencies are similar to the one displayed by a heparin tetrasaccharide. After 
demonstrating that this fluorescence polarization assay can be used for the rapid 
screening of a library of compounds, we studied the inhibitory potency of oversulfated 1 
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in more detail. We measured the polarization of samples containing FGF-2, fluorescent 
38 and increasing concentrations of tetrasaccharide 1 (Figure 5). The obtained curve 
was fitted to the equation for a simple one-site competitive interaction. An IC50 value of 
15 µM was estimated for compound 1. In terms of screening for inhibitors, our 
fluorescence polarization competition assay is advantageous over methods that require 
the immobilization of the ligand or the protein on a solid support and are based on the 
inhibition of the interaction that occurs at the surface, because this surface interaction 
can be affected by multivalency, involves unknown amounts of one of the biomolecules 
and requires additional washing and incubation steps.         
The binding of FGF-2 to cell surface heparan sulfate GAGs is essential for tumor 
angiogenesis and growth. Inhibition of angiogenesis is a well established and important 
anti-cancer strategy and, therefore, there is a great interest on compounds that 
potentially inhibit the FGF-2/GAG interaction.78 Our data indicate that CS/DS 
tetrasaccharides 1 and 30 display considerable inhibitory activity and can be considered 
as starting points for the design and synthesis of more active compounds. Moreover, 
recent studies78, 79 indicate that the introduction of lipophilic groups on the structure of 
synthetic antiangiogenic molecules improved the properties of these anticancer agents, 
and, in this context, the activity showed by the di-O-benzylated 30 is particularly 
remarkable.  
Conclusions  
We have prepared a N-TFA-protected galactosamine unit as key building block for the 
synthesis of CS and DS oligosaccharides. While the participating N-TFA group ensures 
the desired 1,2-trans stereochemistry of the glycosidic bond, the temporary introduction 
of a di-tert-butylsilylene group at positions 4 and 6 transforms this moiety in an 
excellent glycosyl acceptor for coupling reactions with uronic acid donors. Our results 
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provide an additional illustration of the profound impact that protecting groups have on 
the success of a glycosylation reaction. Moreover, our protecting group design is 
compatible with the deprotection/sulfation steps required for the preparation of final CS 
and DS sequences. Following this strategy, oversulfated CS/DS-like tetrasaccharide 1 
was successfully synthesized. Importantly, our approach can be easily applied to the 
synthesis of other CS and DS oligosaccharides, bearing different sulfate patterns.  
On the other hand, we have developed a fluorescence polarization assay for the rapid 
screening of the interactions between the synthesized oligosaccharides and proteins. The 
binding is analysed in solution, avoiding the potential artefacts and the additional 
washing steps that are typically associated to assays where the receptor or the ligand is 
immobilized on a solid surface. The only requirement to perform these experiments is 
the preparation of an adequate fluorescent probe. With this probe at hand, we could 
evaluate the relative binding affinities of a small library of non-fluorescent synthetic 
GAG oligosaccharides, including synthesized CS/DS tetrasaccharides 1 and 30, to a 
model heparin-binding protein (FGF-2), by using a competition experiment. Our results 
show that this method is an excellent platform for the fast screening of GAG-protein 
interactions. It requires very little sample (nmol/pmol per well) and can be useful for the 
determination of structure-activity relationships of synthetic GAG sequences, 
contributing to the understanding of the role of these polysaccharides in various 
biological processes.  
Experimental  
General procedures: Thin layer chromatography (TLC) analyses were performed on 
silica gel 60 F254 precoated on aluminium plates (Merck) and the compounds were 
detected by staining with sulfuric acid/ethanol (1:9), with cerium (IV) sulfate 
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(10 g), phosphomolybdic acid (13 g), sulfuric acid (60 mL) solution in water (1 L) or 
with anisaldehyde solution (anisaldehyde (25 mL) with sulfuric acid (25 mL), ethanol 
(450 mL) and acetic acid (1 mL)) followed by heating at over 200ºC. Column 
chromatography was carried out on silica gel 60 (0.2-0.5 mm, 0.2-0.063 mm or 0.040-
0.015 mm; Merck). Optical rotations were determined with a Perkin-Elmer 341 
polarimeter. 1H- and 13C-NMR spectra were acquired on Bruker DPX-300, Avance III-
400 and DRX-500 spectrometers. Unit A refers to the reducing end monosaccharide in 
the NMR data. Electrospray mass spectra (ESI MS) were carried out with an Esquire 
6000 ESI-Ion Trap from Bruker Daltonics. High resolution mass spectra (HR MS) were 
carried out by the Mass Spectrometry Service, CITIUS, Universidad de Sevilla. HR MS 
(electrospray) of compounds 30 and 1 were obtained with a Thermo LTQ Orbitrap 
Velos spectrometer at CCiT, Universitat de Barcelona. Microwave-based sulfation 
reactions were performed using a Biotage Initiator Eight synthesizer in sealed reaction 
vessels. 
Benzyl (4-methoxyphenyl 2-O-benzoyl-3-O-benzyl-β-D-glucopyranoside) uronate 
(6): TEMPO (2 mL of a 0.016 M solution in CH2Cl2), Bu4NBr (2 mL of a 0.08 M 
solution in CH2Cl2) and KBr (0.65 mL of a 0.5 M solution in H2O) were added 
dropwise at 0ºC to a solution of diol 5 (1.6 g, 3.33 mmol) in CH2Cl2 (33 mL). A 
solution of Ca(ClO)2 (1.2 g, 8.3 mmol) and NaHCO3 (1.2 g, 14.3 mmol) in H2O (31 
mL) was then added dropwise at 0ºC. After stirring for 1 h at 0ºC, the reaction was 
quenched by adding Na2SO3 (25 mL of a 0.8 M solution in H2O). After stirring for 15 
min at 0ºC, the reaction mixture was diluted with additional CH2Cl2 and H2O, and the 
organic layer was then separated, washed with a solution of Na2SO3 (0.8 M) and brine, 
dried (MgSO4), filtered, and concentrated. The residue was dissolved in DMF (45 mL) 
and benzyl bromide (0.8 mL, 6.7 mmol) and Bu4NI (0.6 g, 1.7 mmol) were added. The 
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mixture was stirred for 3 h at 60 ºC, diluted with EtOAc, washed with H2O, dried 
(MgSO4), filtered, and concentrated. Flash chromatography (toluene/EtOAc, 13:1) gave 
6 (1.1 g, 56%). TLC (6:1 toluene/EtOAc) Rf 0.41; [α]
20
D  –3.4º (c 1.0, CH2Cl2);
 1H-NMR 
(300 MHz, CDCl3): δ 7.94 (m, 2H, Ar), 7.50 (m, 1H, Ar), 7.36 (m, 2H, Ar), 7.28 (m, 
5H, Ar), 7.09 (m, 5H, Ar), 6.83 (m, 2H, Ar), 6.62 (m, 2H, Ar), 5.42 (dd, 1H, H-2), 5.17 
(2d, 2H, CH2(Bn)), 4.93 (d, 1H, J 1,2 = 7.6 Hz, H-1), 4.70 (2d, 2H, CH2(Bn)), 4.12 (dd, 
1H, J3,4 = J 4,5 = 9.5 Hz, H-4), 3.96 (d, 1H, H-5), 3.71 (dd, 1H, J2,3 = 9.2 Hz, H-3), 3.63 
(s, 3H, Me(OMP)); 13C-NMR (75 MHz, CDCl3): δ 168.9, 165.5 (CO(COOBn, Bz)), 
155.8, 151.3, 138.1, 135.3 (Ar-C), 133.5 (Ar-CH), 130.0, 129.8, 128.8, 128.7, 128.6, 
128.4, 128.2, 127.8, (Ar-C, Ar-CH), 119.3, 114.6 (Ar-CH), 101.5 (C-1), 81.0 (C-3), 
74.8, 74.7 (CH2(Bn), C-5), 73.1 (C-2), 72.0 (C-4), 67.5 (CH2(Bn)), 55.6 (Me(OMP)); 
HR MS: m/z: calcd for C34H32O9Na: 607.1944; found: 607.1946 [M+Na]
+. 
Benzyl (4-methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-levulinoyl-β-D-
glucopyranoside) uronate (7): Compound 6 (2.1 g, 3.6 mmol), 1,3-
dicyclohexylcarbodiimide (1.11 g, 5.39 mmol), DMAP (44 mg, 0.36 mmol) and  
levulinic acid (1.83 mL, 18.0 mmol) were dissolved in  CH2Cl2 (25 mL). After stirring 
for 3 h, the mixture was diluted with CH2Cl2 and washed with saturated aqueous 
NaHCO3. The organic phase was dried with MgSO4, filtered, and concentrated in 
vacuo. The residue was purified by flash cromatography on silica gel (2:1 
hexane/EtOAc) to give 7 as a white solid (1.98 g, 81%). TLC (2:1 hexane/EtOAc) Rf 
0.28; [α]
20
D  +8.4º (c 1.0, CH2Cl2); 
1H-NMR (300 MHz, CDCl3): δ 7.94 (m, 2H, Ar), 
7.52 (m, 1H, Ar), 7.38 (m, 2H, Ar), 7.28 (m, 5H, Ar), 7.09 (m, 5H, Ar), 6.83 (m, 2H, 
Ar), 6.65 (m, 2H, Ar), 5.49 (dd, 1H, J1,2 = 7.2 Hz, J2,3 = 8.9 Hz, H-2), 5.40 (dd, 1H, J3,4 
= 9.0 Hz, J4,5 = 9.6 Hz, H-4), 5.08 (s, 2H, CH2(Bn)), 4.99 (d, 1H, H-1), 4.58 (2d, 2H, 
CH2(Bn)), 4.08 (d, 1H, H-5), 3.88 (dd, 1H, J2,3 = J 3,4 = 8.9 Hz, H-3), 3.66 (s, 3H, 
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Me(OMP)), 2.60-2.17 (m, 4H, CH2(Lev)), 2.05 (s, 3H, CH3(Lev)); 
13C-NMR (75 MHz, 
CDCl3): δ 205.9 (CO(Lev)), 171.2, 166.9, 165.0 (CO (COOBn, Bz, Lev)), 155.9, 151.1, 
137.4, 135.1 (Ar-C), 133.4 (Ar-CH), 129.8, 129.5, 128.6, 128.5, 128.3, 128.0, 127.7, 
(Ar-C, Ar-CH), 119.3, 114.5 (Ar-CH), 101.0 (C-1), 78.9 (C-3), 73.9 (CH2(Bn)), 72.9 
(C-5), 72.8 (C-2), 71.0 (C-4), 67.7 (CH2(Bn)), 55.6 (Me(OMP)), 37.6 (CH2(Lev)), 29.7 
(CH3(Lev)), 27.7 (CH2(Lev)); HR MS: m/z: calcd for C39H38O11Na: 705.2312; found: 
705.2316 [M+Na]+. 
Benzyl 2-O-benzoyl-3-O-benzyl-4-O-levulinoyl-α,β-D-glucopyranosuronate (8): 
CAN (8.1 g, 14 mmol) was added to a solution of the glycoside 7 (1.9 g, 2.8 mmol) in 
toluene–acetonitrile–water (1:6:1, 75 mL) and the mixture was stirred for 1.5 h at r.t. 
The mixture was then diluted with EtOAc, washed with H2O and NaHCO3, dried 
(MgSO4), filtered and concentrated under reduced pressure. Flash chromatography on 
silica gel (toluene/EtOAc 1:0 → 3:1) afforded the corresponding hemiacetal 8 (960 mg, 
60%) as a mixture of α/β anomers (9:1). TLC (2:1 toluene/EtOAc) Rf  0.47; 1H-NMR 
(300 MHz, CDCl3) (for α anomer): δ 8.03 (m, 2H, Ar), 7.58 (m, 1H, Ar), 7.43 (m, 2H, 
Ar), 7.34 (m, 5H, Ar), 7.21 (m, 5H, Ar), 5.68 (d, 1H, J 1,2 = 3.4 Hz, H-1), 5.29 (dd, 1H, 
J 3,4 = J 4,5 = 8.9 Hz, H-4), 5.16 (dd, 1H, H-2), 5.06 (2d, 2H, CH2(Bn)), 4.70 (2d, 2H, 
CH2(Bn)), 4.61 (d, 1H, J 4,5 = 8.9 Hz, H-5), 4.23 (dd, 1H, J 2,3 = J 3,4 = 8.9 Hz, H-3), 
2.58-2.21 (m, 4H, CH2(Lev)), 2.09 (s, 3H, CH3(Lev)); 
13C-NMR (75 MHz, CDCl3) (for 
α anomer): δ 206.4 (CO(Lev)), 171.4, 168.5, 165.7 (CO (COOBn, Bz, Lev)), 137.9-
127.7 (Ar), 90.3 (C-1), 76.1(C-3), 74.8 (CH2(Bn)), 72.9 (C-2), 71.0 (C-4), 68.9 (C-5), 
68.0 (CH2(Bn)), 37.6 (CH2(Lev)), 29.7 (CH3(Lev)), 27.7 (CH2(Lev)); 
1H-NMR (300 
MHz, CDCl3) (selected data for β anomer): δ 7.99 (m, 2H, Ar), 7.58 (m, 1H, Ar), 7.43 
(m, 2H, Ar), 7.26 (m, 5H, Ar), 7.18 (m, 5H, Ar), 5.37 (dd, 1H, J 3,4 = J 4,5 = 9.0 Hz, H-
4), 5.20 (dd, 1H, H-2), 4.86 (d, 1H, J 1,2 = 6.9 Hz, H-1), 4.15 (d, 1H, J 4,5 = 9.2 Hz, H-5), 
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3.95 (dd, 1H, J 2,3 = J 3,4 = 8.3 Hz, H-3), 2.58-2.21 (m, 4H, CH2(Lev)), 2.09 (s, 3H, 
CH3(Lev)); 
13C-NMR (75 MHz, CDCl3) (selected data for β anomer from HMQC 
experiment): δ 96.3 (C-1), 77.6 (C-3), 72.7 (C-5),  70.8 (C-4); HR MS: m/z: calcd for 
C32H32O10Na: 599.1893; found: 599.1911 [M+Na]
+. 
O-(Benzyl 2-O-benzoyl-3-O-benzyl-4-O-levulinoyl-α,β-D-glucopyranosyluronate) 
trichloroacetimidate (2): Trichloroacetonitrile (0.83 mL, 8.3 mmol) and K2CO3 (126 
mg, 0.91 mmol) were added to 8 (480 mg, 0.83 mmol) in dry CH2Cl2 (4.8 mL). After 
stirring at room temperature for 4 h, the mixture was filtered off and concentrated in 
vacuo to obtain 2 (574 mg, 96%). TLC (2:1 toluene/EtOAc) Rf 0.55; 
1H-NMR (300 
MHz, CDCl3): (for α anomer): δ 8.59 (s, 1H, NH), 7.95 (m, 2H, Ar), 7.58 (m, 1H, Ar), 
7.43 (m, 2H, Ar), 7.37 (m, 5H, Ar), 7.20 (m, 5H, Ar), 6.74 (d, 1H, J 1,2 = 3.3 Hz, H-1), 
5.44 (dd, 1H, H-2), 5.38 (dd, 1H, H-4), 5.15 (2d, 2H, CH2(Bn)), 4.72 (2d, 2H, 
CH2(Bn)), 4.52 (d, 1H, J 4,5 = 10.1 Hz, H-5), 4.29 (dd, 1H, J 2,3 = J 3,4 = 9.7 Hz, H-3), 
2.66-2.20 (m, 4H, CH2(Lev)), 2.12 (s, 3H, CH3(Lev)); 
13C-NMR (75 MHz, CDCl3) (for 
α anomer): δ 206.4 (CO(Lev)), 171.4, 168.5, 165.7 (CO(COOBn, Bz, Lev)), 160.0 
(C=NH), 137.4-127.7 (Ar), 93.1 (C-1), 90.8 (CCl3), 75.7 (C-3), 74.9 (CH2(Bn)), 71.3, 
71.2, 70.9 (C-2, C-5, C-4), 67.9 (CH2(Bn)), 37.6 (CH2(Lev)), 29.7 (CH3(Lev)), 27.7 
(CH2(Lev)); HR MS: m/z: calcd for C34H32Cl3NO10Na: 742.0989; found: 742.0984 
[M+Na]+. 
Methyl (dimethylthexylsilyl 3-O-benzyl-2,4-di-O-levulinoyl-β-L-idopyranoside) 
uronate (10): Lev2O preparation: LevOH (4.7 mL, 45.4 mmol) was added at 0ºC to a 
solution of 1,3-dicyclohexylcarbodiimide (4.68 g, 22.7 mmol) in CH2Cl2 (38 mL). After 
stirring for 5 min at room temperature, the mixture was cooled and filtered to give a 
solution of Lev2O in CH2Cl2. 
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Lev2O (15.0 mL of a 0.76 M solution in CH2Cl2) was added at room temperature to a 
mixture of 9 (1.0 g, 2.3 mmol) and DMAP (41 mg, 0.34 mmol) in dry Py (40 mL). The 
mixture was stirred for 22 h, diluted with CH2Cl2, and washed with 1 M HCl, saturated 
aqueous NaHCO3, and H2O. The organic phase was dried (MgSO4), filtered and 
concentrated to dryness. The residue was purified by column chromatography 
(hexane/EtOAc 2:1) to afford 10 (1.55 g, 98%). TLC (hexane/EtOAc 1:1) Rf 0.26; [α]
20
D  
+19º (c 1.0, CHCl3); 
1H-NMR (300 MHz, CDCl3): δ 7.34 (m, 5H, Ar), 5.16 (m, 1H, H-
4), 5.08 (d, 1H, J1,2 = 1.6 Hz, H-1), 4.93 (m, 1H, H-2), 4.76, 4.69 (2d, 2H, CH2(Bn)), 
4.59 (d, 1H, J4,5 = 2.1 Hz, H-5), 3.86 (t, 1H, J2,3 = J3,4 = 2.7 Hz, H-3), 3.78 (s, 3H, 
COOMe), 2.92-2.50 (m, 8H, CH2(Lev)), 2.18 (s, 6H, CH3(Lev)), 1.61 (hp, 1H, 
CH(CH3)2), 0.87-0.83 (12H, CH(CH3)2, C(CH3)2), 0.23, 0.14 (2s, 6H, Si(CH3)2); 
13C-NMR (75 MHz, CDCl3): δ 206.5, 206.3 (CO(Lev)), 172.3, 172.1 (CO(Lev)), 167.9 
(COOMe), 137.3 (Ar-C), 128.6, 128.2, 127.8 (Ar-CH), 93.1 (C-1), 74.4 (C-3), 73.1 
(CH2(Bn)), 72.7 (C-5), 68.0 (C-2), 67.2 (C-4), 52.4 (COOMe), 38.0, 37.8 (CH2(Lev)), 
34.1 (CH(CH3)2), 30.0, 29.9 (CH3(Lev)), 28.1 (CH2(Lev)), 25.0 (C(CH3)2), 20.3, 20.0, 
18.7, 18.5 (CH(CH3)2, C(CH3)2), -1.8, -3.5 (Si(CH3)2); HR MS: m/z: calcd for 
C32H48O11SiNa: 659.2864; found: 659.2847 [M+Na]
+.  
Methyl 3-O-benzyl-2,4-di-O-levulinoyl-α,β-L-idopyranosuronate (11): An excess of 
(HF)n·Py (7.2 mL) was added at −10°C under an argon atmosphere to a solution of 10 
(1.63 g, 2.56 mmol) in dry THF (37 mL). After 19 h at 0ºC the mixture was diluted with 
CH2Cl2 and washed with H2O and saturated NaHCO3 solution until neutral pH. The 
organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (toluene/EtOAc 1:3) to afford 11 as a mixture of 
α/β anomers (1:1) (970 mg, 77%). TLC (hexane/EtOAc 1:2) Rf 0.13; 1H-NMR (300 
MHz, CDCl3): δ 7.34 (m, 10H, Ar, Ar’), 5.30 (m, 1H, H-1), 5.26 (m, 1H, H-4), 5.16 (m, 
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1H, H-4’), 5.14 (bs, 1H, H-1’), 4.98 (d, 1H, J4,5 = 2.3 Hz, H-5), 4.95 (m, 1H, H-2’), 4.85 
(m, 1H, H-2), 4.78, 4.74 (2m, 4H, CH2(Bn), CH2(Bn)’), 4.69 (d, 1H, J4,5 = 2.0 Hz, H-
5’), 4.18 (bd, 1H, OH), 3.96 (bt, 2H, H-3, H-3’), 3.81, 3.80 (2s, 6H, COOMe, 
COOMe’), 2.91-2.45 (m, 16H, CH2(Lev), CH2(Lev)’), 2.19-2-17 (3s, 12H, CH3(Lev), 
CH3(Lev)’); 13C-NMR (75 MHz, CDCl3): δ 207.3, 206.5, 206.3 (CO(Lev), CO(Lev)’), 
172.4, 171.9, 171.8 (CO(Lev), CO(Lev)’), 168.8, 168.1 (COOMe, COOMe’),  137.0, 
136.6 (Ar-C), 129.1, 128.7, 128.6, 128.4, 128.3, 128.2, 128.0, 127.8 (Ar-C, Ar-CH), 
93.0 (C-1), 92.1 (C-1’), 73.5, 73.4 (CH2(Bn), CH2(Bn)’), 73.1, 72.7, 72.3 (C-3, C-3’, 
C-5’), 68.0 (C-2’), 67.1 (C-4, C-4’), 66.7 (C-2), 65.6 (C-5), 52.6 (COOMe, COOMe’), 
38.1, 37.8, 37.7 (CH2(Lev), CH2(Lev)’), 29.8 (CH3(Lev), CH3(Lev)’), 28.0, 27.9, 27.8 
(CH2(Lev), CH2(Lev)’); HR MS: m/z: calcd for C24H30O11Na: 517.1686; found: 
517.1666 [M+Na]+.  
 O-(Methyl 3-O-benzyl-2,4-di-O-levulinoyl-α,β-L-idopyranosyluronate) 
trichloroacetimidate (3): K2CO3 (207 mg, 1.67 mmol) and trichloroacetonitrile (3.0 
mL, 30 mmol) were added at room temperature to a solution of 11 (750 mg, 1.52 mmol) 
in dry CH2Cl2 (15 mL). After stirring for 11 h at room temperature, the reaction mixture 
was filtered through a pad of Celite and concentrated to dryness to obtain 3 as a mixture 
of α/β anomers (920 mg, 95%).  TLC (toluene/EtOAc 1:4) Rf 0.44, 0.58 (α and β 
anomers); 1H-NMR (300 MHz, CDCl3) (data for major anomer): δ 8.68 (s, 1H, NH), 
7.34 (m, 5H, Ar), 6.23 (d, 1H, J1,2 = 1.8 Hz, H-1), 5.27 (m, 1H, H-2), 5.22 (m, 1H, H-4), 
4.80 (d, 1H, J4,5 = 2.0 Hz, H-5), 4.80-4.68 (m, 2H, CH2(Bn)), 3.99 (t, 1H, J2,3 = J3,4 = 3.0 
Hz, H-3), 3.78 (s, 3H, COOMe), 2.90-2.49 (m, 8H, CH2(Lev)), 2.16 (s, 6H, CH3(Lev)); 
13C-NMR (75 MHz, CDCl3) (data for major anomer): δ 206.4, 206.3 (CO(Lev)), 172.1, 
172.0 (CO(Lev)), 167.2 (COOMe), 160.4 (C=NH), 136.9 (Ar-C), 128.6, 128.3, 127.9 
(Ar-CH), 94.4 (C-1), 90.8 (CCl3), 73.6 (C-3), 73.4 (CH2(Bn)), 73.2 (C-5), 67.3 (C-4), 
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65.8 (C-2), 52.7 (COOMe), 37.8, 37.7 (CH2(Lev)), 29.9, 29.8 (CH3(Lev)), 28.0, 27.9 
(CH2(Lev));
 1H-NMR (300 MHz, CDCl3) (data for minor anomer): δ 8.69 (s, 1H, NH), 
7.34 (m, 5H, Ar), 6.40 (bs, 1H, H-1), 5.27 (m, 1H, H-4), 5.11 (m, 1H, H-2), 5.04 (d, 1H, 
J4,5 = 1.8 Hz, H-5), 4.80-4.68 (m, 2H, CH2(Bn)), 3.87 (m, 1H, H-3), 3.78 (s, 3H, 
COOMe), 2.90-2.49 (m, 8H, CH2(Lev)), 2.17 (s, 6H, CH3(Lev)); 
13C-NMR (75 MHz, 
CDCl3) (data for minor anomer): δ 206.4, 206.3 (CO(Lev)), 171.8, 171.7 (CO(Lev)), 
168.1 (COOMe), 160.1 (C=NH), 137.2 (Ar-C), 128.4, 127.9, 127.7 (Ar-CH), 95.0 
(C-1), 90.5 (CCl3), 72.6 (CH2(Bn)), 71.5 (C-3), 67.8 (C-5), 67.3 (C-4), 65.2 (C-2), 52.7 
(COOMe), 37.9, 37.8 (CH2(Lev)), 29.9, 29.8 (CH3(Lev)), 28.0, 27.9 (CH2(Lev)); HR 
MS: m/z: calcd for C26H30Cl3NO11Na: 660.0782; found: 660.0782 [M+Na]
+. 
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-trifluoroacetamido-α,β-D-galactopyranose (12)61, 
62: Galactosamine  hydrochloride (21 g, 93.4 mmol) was suspended in MeOH (250 mL). 
NaOMe (105 mL, 1.3 M solution in MeOH) was added at room temperature. After 
stirring for 30 min, TFA anhydride (14.2 mL, 98.1 mmol) was added at 0ºC. After 
stirring for 10 min, Et3N (13.6 mL, 94.0 mmol) was added. After stirring for 28 h at 
room temperature, the reaction mixture was concentrated in vacuo. The residue was 
dissolved in Py (420 ml) and DMAP (6.4 g, 46.7 mmol) and acetic anhydride (105.8 
mL, 1.1 mol) were added at 0 ºC. The reaction was stirred for 72 h at room temperature, 
diluted with EtOAc, washed with H2O, 1 M HCl and NaHCO3, dried (MgSO4), filtered, 
and concentrated. Flash chromatography (hexane/EtOAc, 3:1) gave 12 (28.4 g, 66%) as 
a mixture of α/β anomers (1:0.8). TLC (2:1 hexane/EtOAc) Rf 0.27; 1H-NMR (300 
MHz, CDCl3) (data for α anomer): δ 6.55 (bs, 1H, NH), 6.28 (d, 1H, J 1,2 = 3.6 Hz, H-
1), 5.46 (dd, 1H, H-4), 5.29 (dd, 1H, J 2,3 = 11.4 Hz, J 3,4 = 3.5 Hz, H-3), 4.68 (m, 1H, 
H-2), 4.28-4.03 (m, 3H, H-5, H-6a, H-6b), 2.18-2.00 (m, 12H, CH3); 
1H-NMR (300 
MHz, CDCl3) (data for β anomer): δ 7.02 (bs, 1H, NH), 5.77 (d, 1H, J 1,2 = 8.7 Hz, H-
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1), 5.40 (dd, 1H, H-4), 5.18 (dd, 1H, J 2,3 = 11.3 Hz, J 3,4 = 3.3 Hz, H-3), 4.49 (m, 1H, 
H-2), 4.28-4.03 (m, 3H, H-5, H-6a, H-6b), 2.18-2.00 (m, 12H, CH3); ESI MS: m/z: 
calcd for C16H20F3NO10Na: 466.1; found: 466.1 [M+Na]
+. 
4-Methoxyphenyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-β-D-
galactopyranoside (13): TMSOTf (320 µL, 1.7 mmol) was added to a cooled (0ºC) 
solution of 12 (5.1 g, 11.5 mmol) and 4-methoxyphenol (2.6 g, 20.7 mmol) in dry 
CH2Cl2 (51 mL). The mixture was stirred for 1 h at 0ºC and TEA (1 mL) was then 
added. The mixture was diluted with EtOAc and washed with H2O, saturated aqueous 
NaHCO3 and H2O. The organic phase was dried (MgSO4), filtered, and concentrated. 
The residue was purified by silica gel chromatography (toluene/EtOAc 4:1 → 1:1) to 
give 13 (2.4 g, 42%) and starting material (α anomer, 2.4 g, 40%). TLC (4:1 
toluene/EtOAc) Rf 0.17; [α]
20
D  – 3.5 º (c 1.0, CHCl3); 
1H-NMR (300 MHz, CDCl3): δ 
6.98 (d, 1H, J2,NH = 9.1 Hz, NH), 6.92 (m, 2H, Ar), 6.78 (m, 2H, Ar), 5.41 (d,  1H, J3,4 = 
2.9 Hz, H-4), 5.31 (dd, 1H, J2,3 = 11.3 Hz, H-3), 5.04 (d, 1H, J1,2 = 8.3 Hz, H-1), 4.40 
(m, 1H, H-2), 4.26-4.12 (2dd, 2H, J6a,6b = 11.5 Hz, H-6a, H-6b), 4.03 (br dd, 1H, J5,6a = 
J5,6b = 6.5 Hz, H-5), 3.76 (s, 3H, Me(OMP)), 2.18-2.00 (3s, 9H, CH3(Ac)); 
13C-NMR 
(75 MHz, CDCl3): δ 170.7, 170.6,  170.3 (COCH3), 158.0 (q, 2JC,F = 34.1 Hz, COCF3), 
155.9, 151.0 (Ar-C), 118.8, 114.7 (Ar-CH), 115.6 (q, 1JC,F = 287.0 Hz, COCF3), 100.4 
(C-1), 71.1 (C-5), 69.5 (C-3), 66.4 (C-4), 61.6 (C-6), 55.7 (Me(OMP)), 51.8 (C-2), 20.5 
(CH3(Ac)) ; HR MS: m/z: calcd for C21H24NO10F3Na: 530.1250 ; found: 530.1268 
[M+Na]+. 
4-Methoxyphenyl 3,4,6-trihydroxy-2-deoxy-2-(trifluoroacetamido)-β-D-
galactopyranoside (14): Compound 13 (2.8 g, 5.5 mmol) was dissolved in MeOH (39 
mL) and NaOMe (365 µL, 2.17 M solution in MeOH) was added.  After 50 min, 
Amberlite acidic resin was added until pH 7. The Amberlite resin was filtered off, and 
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the solvent was removed in vacuo to give 14 (2.1 g, quantitative).  TLC (16:1 CH2Cl2 
/MeOH) Rf 0.21; 
1H NMR (300 MHz, MeOD): δ 6.97 (m, 2H, Ar), 6.82 (m, 2H, Ar), 
4.91 (d, 1H, J1,2 = 8.5 Hz, H-1), 4.25 (dd, 1H, J2,3 = 10.7 Hz, H-2), 3.91 (d,  1H, J3,4 = 
3.1 Hz, H-4), 3.87-3.71 (m, 6H, H-6a, H-6b, H-3, CH3(OMP)), 3.64 (dd, 1H,  H-5); HR 
MS: m/z: calcd for C15H18NO7F3Na: 404.0933; found: 404.0923 [M+Na]
+. 
4-Methoxyphenyl 4,6-O-benzylidene-2-deoxy-2-trifluoroacetamido-β-D-
galactopyranoside (15): Benzaldehyde dimethyl acetal (1.0 mL, 6.7 mmol) and p-
toluenesulfonic acid (0.08 g, 0.45 mmol) were added to a solution of  14 (1.7 g, 4.5 
mmol) in MeCN (31 mL). After stirring at room temperature for 4 h, EtOAc was added 
and the mixture was washed with saturated aqueous NaHCO3. The organic phase was 
dried with MgSO4, filtered and concentrated in vacuo. Flash chromatography ( 
toluene/acetone 5:1 → 1:1) gave 15 (1.8 g, 87%). TLC (2:1 toluene/acetone) Rf 0.43; 
[α]
20
D  – 8.4º (c 1.0, acetone); 
1H-NMR (400 MHz, (CD3)2CO): δ 8.56 (d, 1H, J2,NH = 9.4 
Hz, NH), 7.59 (m, 2H, Ar), 7.40 (m, 3H, Ar), 7.02 (m, 2H, Ar), 6.86 (m, 2H, Ar), 5.72 ( 
s, 1H, PhCHO), 5.19 (d, 1H, J1,2 = 8.3 Hz, H-1), 4.48-4.35 (m, 3H, H-2, H-4, OH), 4.32-
4.18 (m, 2H, H-6a, H-6b), 4.16-4.06 (m, 1H, H-3), 3.85 (s, 1H, H-5), 3.76 (s, 3H, Me 
(OMP)), 13C-NMR (100 MHz, (CD3)2CO): δ 157.3 (q, 2JC,F = 36.0 Hz, COCF3), 155.5-
115.5 (Ar), 116.3 (q, 1JC,F = 289.0 Hz, COCF3), 100.7 (PhCHO), 100.3 (C-1), 75.4 (C-
4), 69.8 (C-3), 68.8 (C-6), 66.9 (C-5), 55.0 (Me(OMP)), 53.8 (C-2); HR MS: m/z: calcd 
for C22H22NO7F3Na: 492.1246; found: 492.1234 [M+Na]
+. 
Dimethylthexylsilyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-β-D-
galactopyranoside (16):  Benzylamine (3.0 mL, 28 mmol) was added to a solution of 
12 (4.0 g, 9.0 mmol) in THF (40 mL). After stirring for 3 h at room temperature, the 
mixture was diluted with CH2Cl2, and washed with 1M HCl and H2O. The organic 
phase was dried over Mg2SO4, filtered and the solvent was removed under reduced 
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pressure. The residue [TLC (3:2 hexane/EtOAc) Rf 0.36] (3.9 g) was dissolved in 
CH2Cl2 (19.5 mL). Imidazole (1.78 g, 26.2 mmol) and thexyldimethylsilyl chloride 
(2.30 mL, 11.7 mmol) were added. After 24 h, the mixture was diluted with CH2Cl2 and 
washed with H2O. The organic layer was dried over MgSO4, filtered, and the solvent 
was removed in vacuo. Flash chromatography on silica gel (3:1 hexane/EtOAc) 
afforded 16 (2.43 g, 51%). TLC (3:1 hexane/EtOAc) Rf 0.33; []
20
D -8.7º (c 1.0, CHCl3); 
1H-NMR (400 MHz, CDCl3):  6.71 (d, 1H, J 2,NH = 9.3 Hz, NH), 5.38  (dd, 1H, J 3,4 = 
3.8 Hz, H-4), 5.22 (dd, 1H, J 3,4 = 3.5 Hz, J 2,3 = 11.3 Hz, H-3), 4.84 (d, 1H, J 1,2 = 8.0 
Hz, H-1), 4.29- 4.08 (m, 3H, H-2, H-6a, H-6b), 3.95 (m, 1H, H-5), 2.28-1.94 (3s, 9H, 
COCH3), 1.62 (m, 1H, CH(CH3)2), 0.97-0.76 (m, 12H, C(CH3)2 and CH(CH3)2), 0.29-
0.07 (2s, 6H, Si(CH3)2); 
13C-NMR (100 MHz, CDCl3):  170.9, 170.6, 170.4 (COCH3), 
157.3 (q, 2JC,F = 36.9 Hz, COCF3), 115.8 (q, 
1JC,F = 290.0 Hz, COCF3), 96.0 (C-1), 71.0 
(C-5), 69.8 (C-3), 66.8 (C-4), 61.9 (C-6), 53.6 (C-2), 33.9, 24.8, 20.7, 20.5, 19.8, 18.4 
(TDS, OAc), -2.0, -3.0 (TDS); HR MS: m/z: calcd for C22H36NO9F3NaSi: 566.2009; 
found: 566.1991 [M+Na]+. 
Dimethylthexylsilyl 6-O-chloroacetyl-2-deoxy-2-trifluoroacetamido-β-D-
galactopyranoside (18): Compound 16 (2.2 g, 4.1 mmol) was dissolved in MeOH (31 
mL) and NaOMe (273 µL, 2.17 M solution in MeOH) was added.  After 50 min, 
Amberlite acidic resin was added until pH 7. The Amberlite resin was filtered off, and 
the solvent was removed in vacuo to give the desired triol (1.7 g, quantitative). An 
aliquot of this triol (0.5 g, 1.2 mmol) was dissolved in anhydrous CH2Cl2 (45 mL) and 
collidine (4.5 mL), and chloroacetic anhydride (112 µL, 1.4 mmol) was then added 
dropwise at -60 ºC. After stirring for 1 h at -60 ºC, the mixture was diluted with EtOAc 
and washed with 1M HCl, NaHCO3 and H2O. The organic phase was dried (MgSO4), 
filtered, and concentrated. Flash silica chromatography (3:2 hexane/EtOAc) afforded 18 
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(454 mg, 77%). TLC (3:2 hexane/EtOAc) Rf 0.14; []
20
D + 17 º (c 1.0, MeOH); 
1H-
NMR (300 MHz, CDCl3):  7.31 (d, 1H, J 2,NH = 7.9 Hz, NH), 4.70  (d, 1H, J 1,2 = 7.5 
Hz, H-1),  4.56-4.30 (m, 2H, H-6a, H-6b), 4.10 (s, 2H, COCH2Cl), 4.02-3.80 (m, 3H, H-
3, H-4, H-2), 3.75 (m, 1H, H-5), 1.58 (m, 1H, CH(CH3)2), 0.98-0.70 (m, 12H, C(CH3)2 
and CH(CH3)2), 0.23-0.03 (2s, 6H, Si(CH3)2); 
13C-NMR (75 MHz, CDCl3):  167.7 
(COCH2Cl), 159.0 (q, 
2JC,F = 36.8 Hz, COCF3), 115.8 (q, 
1JC,F = 285.0 Hz, COCF3), 
95.8 (C-1), 72.5 (C-5), 70.4, 68.3 (C-3, C-4), 65.1 (C-6), 55.9 (C-2), 40.5 (CH2Cl), 33.9, 
24.8, 19.8, 18.5 (Ac, TDS), -2.0, -4.0 (TDS); ESI MS: m/z: calcd for 
C18H31ClF3NO7SiNa: 516.2; found: 516.2 [M+Na]
+. 
4-Methoxyphenyl 4,6-O-di-tert-butylsilylene-2-deoxy-2-trifluoroacetamido-β-D-
galactopyranoside (4): Compound 14 (0.66 g, 1.73 mmol) was dissolved in dry Py (30 
mL) and cooled (0ºC). Di-tert-butylsilyl bis(trifluoromethanesulfonate) (0.63 mL, 1.9 
mmol) was added and the mixture was stirred at room temperature for 12 min. The 
reaction was quenched with MeOH (3 mL), diluted with EtOAc (120 mL), and washed 
with 1 M HCl, saturated aqueous NaHCO3, and H2O. The organic phase was dried 
(MgSO4), filtered and concentrated to dryness. The residue was purified by column 
chromatography (toluene/EtOAc 5:1) to afford 4 (0.8 g, 89%). TLC (toluene/EtOAc 
3:1) Rf 0.30; [α]
20
D  –17º (c 1.0, CHCl3); 
1H-NMR (300 MHz, CDCl3): δ 6.92 (m, 2H, 
Ar), 6.87 (d, 1H, J2,NH = 9.1 Hz, NH), 6.78 (m, 2H, Ar), 4.97 (d, 1H, J1,2 = 8.4 Hz, H-1), 
4.39 (d, 1H, J3,4 = 2.7 Hz, H-4), 4.24 (m, 2H, H-6a, H-6b), 4.09 (bq, 1H, H-2), 3.89 (dd, 
1H, J2,3 = 10.5 Hz, H-3), 3.75 (s, 3H, Me(OMP)), 3.46 (bs, 1H, H-5), 2.68 (bs, 1H, OH), 
1.09, 1.06 (2s, 18H, C(CH3)3); 
13C-NMR (75 MHz, CDCl3): δ 158.2 (q, 2JC,F = 37.2 Hz, 
COCF3), 155.9, 151.2 (Ar-C), 119.7 (Ar-CH), 115.9 (q, 
1JC,F = 288.0 Hz, COCF3), 
114.6 (Ar-CH), 100.2 (C-1), 72.0 (C-4), 71.5 (C-5), 70.7 (C-3), 66.9 (C-6), 55.7 
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(Me(OMP)), 55.1 (C-2), 27.5 (C(CH3)3), 23.4, 20.9 (C(CH3)3); HR MS: m/z: calcd for 




β-D-galactopyranoside (19): Acceptor 4 (0.18 g, 0.3 mmol) and glucuronic acid 
trichloroacetimidate 2 (0.38 g, 0.5 mmol) were combined in a flask, coevaporated with 
toluene and dried under vacuum. The starting materials were disolved in dry CH2Cl2 (5 
mL) and further dried by stirring over freshly activated 4Å molecular sieves for 15 min. 
TMSOTf (10 µL, 0.05 mmol) was added at 0ºC. After 10 min, the reaction was 
quenched with Et3N (2.5 mL) and filtered, and the solvent was removed under reduced 
pressure. Purification by flash cromathography (8:1 toluene/EtOAc) yielded 19 (345 
mg, 91%). TLC (5:1 toluene/EtOAc) Rf 0.57; [α]
20
D  +16.5º (c 1.0, CH2Cl2); 
1H-NMR 
(500 MHz, CDCl3) δ 8.01 (m, 2H, Ar), 7.62 (m, 1H, Ar), 7.47 (m, 2H, Ar), 7.42-7.31 
(m, 5H, Ar), 7.18-7.07 (m, 5H, Ar), 6.94 (m, 2H, Ar), 6.81(m, 2H, Ar), 5.41-5.30 (m, 
4H, H-2B, H-1B, H-4B, H-1A), 5.18 (2d, 2H, CH2(Bn)),4.68-4.53 (m, 3H, H-4A, 
CH2(Bn)), 4.43 (dd, 1H, J2,3 = 11.3 Hz, J3,4 = 2.4 Hz, H-3A), 4.21-4.03 (m, 4H, H-6aA, 
H-6bA, H-5B, H-2A), 3.86 (dd, 1H, J2,3 = J3,4 = 8.7 Hz, H-3B), 3.78 (s, 3H, Me(OMP)), 
3.42 (s, 1H, H-5A), 2.62-2.22 (m, 4H, CH2(Lev)), 2.13 (s, 3H, CH3(Lev)), 1.09, 0.98 
(2s, 18H, C(CH3)3); 
13C-NMR (100 MHz, CDCl3): δ 206.0 (CO(Lev)), 171.3, 167.0, 
164.9 (CO(COOBn, Bz, Lev)), 157.6 (q, 2JC,F = 38.6 Hz, COCF3), 155.8, 151.1, 137.2, 
134.6 (Ar-C), 133.5 (Ar-CH), 129.8-127.8 (Ar), 120.0 (Ar-CH), 115.5 (q, 1JC,F = 288.5 
Hz, COCF3), 114.5 (Ar-CH), 99.5, 99.4 (C-1B, C-1A), 79.6 (C-3B), 74.5 (C-3A), 74.2 
(CH2(Bn)), 73.2 (C-4A), 72.5 (C-4B or C-2B),  72.2 (C-5B), 71.3 (C-5A), 70.7 (C-2B 
or C-4B), 68.1 (CH2(Bn)), 67.0 (C-6A), 55.6 (Me(OMP)), 53.7 (C-2A),  37.6 
(CH2(Lev)), 29.8 (CH3(Lev)), 27.7, 27.6, 27.4 (CH2(Lev), C(CH3)3), 23.2, 20.8 
 25 




D-galactopyranoside (20): Donor 3 (0.92 g, 1.44 mmol) and acceptor 4 (0.5 g, 0.96 
mmol) were dissolved in dry CH2Cl2 (12 mL) in the presence of freshly activated 4Å 
molecular sieves. After stirring for 30 min at 0ºC, TMSOTf (348 µL of a 0.41 M 
solution in dry CH2Cl2) was added under an argon atmosphere. After stirring for 15 min 
at 0ºC, the reaction mixture was neutralized with Et3N and concentrated to dryness. The 
residue was purified by column chromatography (toluene/EtOAc 1:1) to afford 20 (756 
mg, 79%). TLC (toluene/EtOAc 1:1) Rf 0.19; [α]
20
D  –18º (c 1.0, CHCl3); 
1H-NMR (300 
MHz, CDCl3): δ 7.34-7.27 (m, 5H, Ar), 7.00 (d, 1H, J2,NH = 7.2 Hz, NH), 6.94 (m, 2H, 
Ar), 6.79 (m, 2H, Ar), 5.34 (d, 1H, J1,2 = 8.3 Hz, H-1A), 5.28 (bt, 1H, H-4B), 5.15 (bs, 
1H, H-1B), 5.07 (d, 1H, J4,5 = 2.6 Hz, H-5B), 4.88 (bt, 1H, H-2B), 4.72 (m, 2H, 
CH2(Bn)), 4.54 (bd, 1H, H-4A), 4.35 (dd, 1H, J2,3 = 11.0 Hz, J3,4 = 2.3 Hz, H-3A), 4.20 
(m, 2H, H-6aA, H-6bA), 3.99 (m, 1H, H-2A), 3.80-3.75 (m, 7H, H-3B, Me(OMP), 
COOMe), 3.48 (bs, 1H, H-5A), 2.83-2.44 (m, 8H, CH2(Lev)), 2.16 (s, 6H, CH3(Lev)), 
1.06, 0.97 (2s, 18H, C(CH3)3);
 13C-NMR (75 MHz, CDCl3): δ 206.8, 206.3 (CO(Lev)), 
171.7, 171.6 (CO(Lev)), 168.9 (COOMe), 157.8 (q, 2JC,F = 36.8 Hz, COCF3), 155.9, 
151.2, 138.0 (Ar-C), 128.4, 127.7, 127.5, 120.0 (Ar-CH), 115.6 (q, 1JC,F = 287.8 Hz, 
COCF3), 114.6 (Ar-CH), 100.3 (C-1B), 99.1 (C-1A), 78.1 (C-3A), 73.3 (C-3B), 72.7, 
72.6 (C-4A, CH2(Bn)), 71.3 (C-5A), 68.6 (C-4B), 67.8 (C-2B), 67.4 (C-5B), 67.0 
(C-6A), 55.7 (COOMe or Me(OMP)), 54.0 (C-2A), 52.6 (COOMe or Me(OMP)), 37.9, 
37.8 (CH2(Lev)), 29.9 (CH3(Lev)), 28.0, 27.7, 27.4 (CH2(Lev), C(CH3)3), 23.3, 20.9 
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galactopyranoside (22): An excess of (HF)n·Py (1.26 mL, 48.3 mmol) was added at 
0°C under an argon atmosphere to a solution of 20 (250 mg, 0.25 mmol) in dry THF (5 
mL). After 23 h at 0ºC the mixture was diluted with CH2Cl2 and washed with H2O and 
saturated NaHCO3 solution until neutral pH. The organic layers were dried (MgSO4), 
filtered and concentrated in vacuo to give 21 (209 mg, 97%). TLC (toluene/acetone 3:2) 
Rf 0.21; 
1H-NMR (300 MHz, CDCl3): δ 7.87 (d, 1H, J2,NH = 7.1 Hz, NH), 7.36-7.24 (m, 
5H, Ar), 6.96 (m, 2H, Ar), 6.80 (m, 2H, Ar), 5.47 (d, 1H, J1,2 = 8.5 Hz, H-1A), 5.23 (m, 
2H, H-4B, H-1B), 4.98 (t, 1H, J1,2 = J2,3 = 5.5 Hz, H-2B), 4.88 (d, 1H, J4,5 = 4.7 Hz, H-
5B), 4.68 (s, 2H, CH2(Bn)), 4.48 (dd, 1H, J2,3 = 10.8 Hz, J3,4 = 3.1 Hz, H-3A), 4.20 (d, 
1H, H-4A), 3.99 (dd, 1H, J5,6a = 6.6 Hz, J6a,6b = 11.8 Hz, H-6aA), 3.95-3.82 (m, 3H, H-
2A, H-6bA, H-3B), 3.80, 3.76 (2s, 6H, Me(OMP), COOMe), 3.71 (bt, 1H, H-5A), 2.94-
2.28 (m, 8H, CH2(Lev)), 2.17 (s, 6H, CH3(Lev));
 13C-NMR (75 MHz, CDCl3) (selected 
data from HSQC experiment): δ 129-127 (Ar-CH), 118.8, 114.2 (Ar-CH), 99.0 (C-1B), 
98.3 (C-1A), 75.9 (C-3A), 74.9 (C-3B), 74.0 (C-5A), 73.0 (CH2(Bn)), 70.5 (C-2B), 69.7 
(C-5B), 69.3 (C-4B), 68.4 (C-4A), 62.3 (C-6A), 55.3 (COOMe or Me(OMP)), 53.9 
(C-2A), 52.3 (COOMe or Me(OMP)), 37.4 (CH2(Lev)), 29.4 (CH3(Lev)), 27.3 
(CH2(Lev); HR MS: m/z: calcd for C39H46F3NO17Na: 880.2616; found: 880.2617 
[M+Na]+. 
21 (152 mg, 0.177 mmol) was dissolved in dry Py (7 mL), cooled (0ºC) and Ac2O (0.5 
mL) was added. After stirring for 48 h at room temperature, the reaction mixture was 
diluted with CH2Cl2 and washed with 1M HCl aqueous solution, saturated NaHCO3 
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aqueous solution and brine. The organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by column chromatography 
(toluene/acetone 3:1) to afford 22 (149 mg, 89%). TLC (toluene/acetone 3:2) Rf 0.49; 
[α]
20
D  -17º (c 1.0, CHCl3); 
1H-NMR (300 MHz, CDCl3): δ 7.77 (d, 1H, J2,NH = 7.4 Hz, 
NH), 7.36-7.27 (m, 5H, Ar), 6.95 (m, 2H, Ar), 6.79 (m, 2H, Ar), 5.44 (d, 1H, J1,2 = 8.6 
Hz, H-1A), 5.41(d, 1H, J3,4 = 3.1 Hz, H-4A), 5.28 (bt, 1H, H-4B), 5.01 (d, 1H, J1,2 = 3.9 
Hz, H-1B), 4.92 (bt, 1H, J2,3 = 5.5 Hz, H-2B), 4.88 (d, 1H, J4,5 = 3.3 Hz, H-5B), 4.63 (q, 
2H, CH2(Bn)), 4.58 (dd, 1H, J2,3 = 10.4 Hz, J3,4 = 3.9 Hz, H-3A), 4.18-4.06 (m, 2H, 
H-6aA, H-6bA), 3.99 (bt, 1H, H-5A), 3.86 (m, 1H, H-2A), 3.80-3.75 (m, 7H, H-3B, 
Me(OMP), COOMe), 2.92-2.33 (m, 8H, CH2(Lev)), 2.19, 2.17 (2s, 6H, CH3(Lev)), 
2.03, 1.92 (2s, 6H, CH3(Ac));
 13C-NMR (75 MHz, CDCl3): δ 207.8, 206.3 (CO(Lev)), 
171.5, 171.4, 170.5, 170.4 (CO(Lev, Ac)), 168.7 (COOMe), 157.9 (q, 2JC,F = 37.5 Hz, 
COCF3), 155.9, 151.1, 137.6 (Ar-C), 128.5, 127.9, 119.1 (Ar-CH), 115.6 (q, 
1JC,F = 
288.1 Hz, COCF3), 114.6 (Ar-CH), 100.3 (C-1B), 99.0 (C-1A), 75.0 (C-3B),  73.7 (C-
3A), 73.2 (CH2(Bn)), 71.3 (C-5A), 69.9 (C-4B), 69.4 (C-2B), 68.8 (C-4A), 68.6 (C-5B), 
61.7 (C-6A), 55.7 (COOMe or Me(OMP)), 55.2 (C-2A), 52.5 (COOMe or Me(OMP)), 
37.9, 37.7 (CH2(Lev)), 29.8 (CH3(Lev)), 27.9, 27.6 (CH2(Lev), 20.7, 20.4 (CH3(Ac)); 
HR MS: m/z: calcd for C43H50F3NO19Na: 964.2827; found: 964.2841 [M+Na]
+.  
3-O-(Methyl 3-O-benzyl-2,4-di-O-levulinoyl-α-L-idopyranosyluronate)-4,6-di-O-
acetyl-2-deoxy-2-trifluoroacetamido-α,β-D-galactopyranose (23): CAN (0.75 mL of 
a 0.63 M solution in H2O) was added to a solution of 22 (149 mg, 0.158 mmol) in 
toluene/MeCN (1:6; 5.25 mL), and the mixture was vigorously stirred for 1 h 20 min at 
0ºC. It was then diluted with EtOAc, washed with H2O, saturated aqueous NaHCO3, 
and H2O. The organic phase was dried (MgSO4), filtered and concentrated to dryness. 
The residue was purified by column chromatography (toluene/acetone 5:2) to afford 23 
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(100 mg, 76%) as a mixture of α/β anomers. TLC (toluene/acetone 3:2) Rf 0.34, 0.31; 
1H-NMR (300 MHz, CDCl3) (data for α anomer): δ 7.39-7.26 (m, 5H, Ar), 6.73 (d, 1H, 
J2,NH = 9.3 Hz, NH), 5.40 (d, 1H, J3,4 = 3.0 Hz, H-4A), 5.37 (d, 1H, J1,2 = 3.1 Hz, H-
1A), 5.20 (bt, 1H, H-4B), 5.06 (bs, 1H, H-1B), 4.92 (d, 1H, J4,5 = 2.3 Hz, H-5B),  4.80 
(m, 1H, H-2B), 4.63 (q, 2H, CH2(Bn)), 4.58 (m, 1H, H-2A), 4.36 (bt, 1H, H-5A), 4.13 
(dd, 1H, J2,3 = 10.8 Hz, H-3A), 4.07 (dd, 1H, J5,6a = 5.3 Hz, J6a,6b = 11.5 Hz, H-6aA), 
3.97 (dd, 1H, J5,6b = 7.0 Hz, H-6bA), 3.81 (s, 3H, COOMe), 3.75 (bt, 1H, H-3B), 3.27 
(bs, 1H, OH), 2.84-2.48 (m, 8H, CH2(Lev)), 2.18 (s, 6H, CH3(Lev)), 2.03, 1.68 (2s, 6H, 
CH3(Ac));
 13C-NMR (75 MHz, CDCl3) (data for α anomer): δ 207.5, 206.4 (CO(Lev)), 
171.7, 171.5, 170.7 (CO(Lev, Ac)), 169.4 (COOMe), 157.8 (q, 2JC,F = 37.3 Hz, COCF3), 
137.4 (Ar-C), 128.5, 128.2, 128.0 (Ar-CH), 115.9 (q, 1JC,F = 288.6 Hz, COCF3), 100.4 
(C-1B), 91.8 (C-1A), 75.0 (C-3A), 72.8 (CH2(Bn)), 72.5 (C-3B), 69.0 (C-4A), 68.4 (C-
4B), 67.7 (C-5A), 67.2 (C-2B), 67.1 (C-5B), 62.3 (C-6A), 52.7 (COOMe), 49.9 (C-2A), 
37.9 (CH2(Lev)), 30.0 (CH3(Lev)), 27.9 (CH2(Lev), 20.9, 20.3 (CH3(Ac)); HR MS: m/z: 




(24): Trichloroacetonitrile (180 µL, 1.8 mmol) and catalytic DBU (107 µL of a 0.084 M 
solution in dry CH2Cl2) were added to a solution of 23 (100 mg, 0.12 mmol) in dry 
CH2Cl2 (2 mL). After stirring for 13 h at room temperature, the reaction mixture was 
concentrated to dryness. The residue was purified by flash chromatography 
(toluene/acetone 5:2 + 1% Et3N) to afford 24 (99 mg, 84%) as a mixture of α/β 
anomers. TLC (toluene/acetone 5:2) Rf 0.42 (α); 1H-NMR (400 MHz, CDCl3) (data for 
α anomer): δ 8.82 (s, 1H, NH(TCA)), 7.36-7.26 (m, 5H, Ar), 6.88 (d, 1H, J2,NH = 9.2 
Hz, NH(TFA)), 6.39 (d, 1H, J1,2 = 3.7 Hz, H-1A), 5.47 (bd, 1H, J3,4 = 2.9 Hz, H-4A), 
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5.18 (bt, 1H, H-4B), 5.13 (bd, 1H, H-1B), 4.87 (d, 1H, J4,5 = 2.7 Hz, H-5B),  4.78 (m, 
1H, H-2B), 4.74 (m, 1H, H-2A), 4.61 (q, 2H, CH2(Bn)), 4.28 (bt, 1H, H-5A), 4.20 (dd, 
1H, J2,3 = 10.9 Hz, H-3A), 4.08 (dd, 1H, J5,6a = 5.9 Hz, J6a,6b = 11.6 Hz, H-6aA), 3.94 
(dd, 1H, J5,6b = 7.1 Hz, H-6bA), 3.78 (s, 3H, COOMe), 3.74 (bt, 1H, H-3B), 2.80-2.46 
(m, 8H, CH2(Lev)), 2.15, 2.13 (2s, 6H, CH3(Lev)), 1.96, 1.72 (2s, 6H, CH3(Ac));
 
13C-NMR (100 MHz, CDCl3) (data for α anomer): δ 206.8, 206.2 (CO(Lev)), 171.6, 
170.4, 170.3 (CO(Lev, Ac)), 168.9 (COOMe), 160.3 (C=NH), 157.7 (q, 2JC,F = 38.0 Hz, 
COCF3), 137.3 (Ar-C), 128.5, 128.1, 128.0 (Ar-CH), 115.7 (q, 
1JC,F = 289.0 Hz, 
COCF3), 100.6 (C-1B), 94.9 (C-1A), 90.7 (CCl3), 75.1 (C-3A), 72.7 (CH2(Bn)), 72.5 
(C-3B), 69.9 (C-5A), 68.2 (C-4A), 68.1 (C-4B), 67.6 (C-2B), 67.2 (C-5B), 61.7 (C-6A), 
52.7 (COOMe), 49.5 (C-2A), 37.8, 37.6 (CH2(Lev)), 29.8 (CH3(Lev)), 27.9, 27.7 
(CH2(Lev), 20.6, 20.1 (CH3(Ac)); ESI MS: m/z: calcd for C38H44Cl3F3N2O18Na: 1001.2; 
found: 1001.1 [M+Na]+.  
4-Methoxyphenyl 3-O-(benzyl 2-O-benzoyl-3-O-benzyl–β-D-
glucopyranosyluronate)-4,6-O-di-tert-butylsilylene-2-deoxy-2-trifluoroacetamido-
β-D-galactopyranoside (25): Compound 19 (0.25 g, 0.23 mmol) was dissolved in 
CH2Cl2 (4 mL), and hydrazine monohydrate (2 mL of a 0.25 M solution in Py/AcOH, 
3:2) was added. After stirring at room temperature for 2 h, the reaction mixture was 
quenched with acetone (1 mL), diluted with CH2Cl2, washed with HCl (1M), saturated 
aqueous NaHCO3 and H2O, dried with MgSO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography on silica gel (9:1 toluene/EtOAc) to give 
25 (0.19 g, 84%). TLC (5:1 toluene/ EtOAc) Rf 0.43; [α]
20
D  +6.1º (c 1.0, CH2Cl2); 
1H-NMR (500 MHz, CDCl3) δ 8.00 (m, 2H, Ar), 7.61 (m, 1H, Ar), 7.46 (m, 2H, Ar), 
7.43- 7.31 (m, 5H, Ar), 7.23-7.12 (m, 5H, Ar), 6.98  (d, 1H, J2,NH = 6.5 Hz, NH), 6.92 
(m, 2H, Ar), 6.81(m, 2H, Ar), 5.44 (d, 1H, J1,2 = 8.2 Hz, H-1A), 5.39 (d, 1H, CH2(Bn)), 
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5.34 (d, 1H, J1,2 = 7.9 Hz, H-1B), 5.29 (dd, 1H, H-2B), 5.20 (d, 1H, CH2(Bn)), 4.77 (2d, 
2H, CH2(Bn)), 4.62 (d, 1H, H-4A), 4.44 (dd, 1H, J2,3 = 11.3 Hz, J3,4 = 2.4 Hz, H-3A), 
4.19-4.05 (m, 2H, H-6aA, H-4B), 4.03-4.91 (m, 3H, H-6bA, H-5B, H-2A), 3.78 (s, 3H, 
Me(OMP)), 3.69 (dd, 1H, J2,3 = J3,4 = 9.2 Hz, H-3B), 3.35 (s, 1H, H-5A), 1.08, 1.00 (2s, 
18H, C(CH3)3); 
13C-NMR (100 MHz, CDCl3): δ 169.0, 165.0 (CO(COOBn, Bz)), 157.7 
(q, 2JC,F = 37.1 Hz, COCF3), 155.9, 151.1, 137.6, 134.4 (Ar-C), 133.5 (Ar-CH), 129.9-
127.8 (Ar), 120.2 (Ar-CH), 115.4 (q, 1JC,F = 286.4 Hz, COCF3), 114.5 (Ar-CH), 100.3 
(C-1B), 99.0 (C-1A), 81.0 (C-3B), 74.9 (C-3A), 74.7 (CH2(Bn)), 73.8 (C-5B), 73.4 (C-
4A), 72.5 (C-2B), 72.2 (C-4B), 71.3 (C-5A), 68.0 (CH2(Bn)), 66.9 (C-6A), 55.6 
(Me(OMP)), 54.2 (C-2A), 27.6, 27.4 (C(CH3)3), 23.2, 20.8 (C(CH3)3); HR MS: m/z: 






trifluoroacetamido-β-D-galactopyranoside (26): Donor 24 (52 mg, 53 µmol) and 
acceptor 25 (35 mg, 35 µmol) were dissolved in dry CH2Cl2 (1.0 mL) in the presence of 
freshly activated 4Å molecular sieves. After stirring for 30 min, TMSOTf (115 µL of a 
0.092 M solution in dry CH2Cl2) was added under an argon atmosphere at 0ºC. After 
stirring for 15 min at 0ºC, the reaction mixture was neutralized with Et3N and 
concentrated to dryness. The residue was purified by column chromatography 
(toluene/acetone 3:1) to afford 26 (47 mg, 74%). TLC (toluene/acetone 3:1) Rf 0.32; 
[α] 20D  –5º (c 1.0, CHCl3); 
1H-NMR (400 MHz, CDCl3): δ 7.93 (d, 2H, Ar), 7.57 (t, 1H, 
Ar), 7.47-7.22 (m, 12H, Ar), 7.06 (m, 5H, Ar), 6.96 (d, 1H, J2,NH = 8.7 Hz, NH), 6.90 
(m, 2H, Ar), 6.83 (d, 1H, J2,NH = 7.0 Hz, NH), 6.78 (m, 2H, Ar), 5.34 (d, 1H, CH2(Bn)), 
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5.33 (d, 1H, J1,2 = 8.6 Hz, H-1A), 5.25 (m, 3H, H-1B, H-2B, H-4D), 5.19 (d, 1H, 
CH2(Bn)), 5.13 (bd, 1H, H-4C), 4.98 (bs, 1H, H-1D), 4.96 (d, 1H, J4,5 = 2.4 Hz, H-5D), 
4.80 (m, 2H, H-2D, CH2(Bn)), 4.64 (m, 2H, CH2(Bn)), 4.57 (d, 1H, J3,4 = 2.5 Hz, H-
4A), 4.51 (d, 1H, CH2(Bn)), 4.37 (dd, 1H, J2,3 = 11.3 Hz, H-3A), 4.18 (d, 1H, J1,2 = 8.5 
Hz, H-1C), 4.12 (bd, 1H, J6a,6b = 12.3 Hz, H-6aA), 4.04 (m, 3H, H-6bA, H-4B, H-2C), 
3.96 (d, 1H, J4,5 = 9.3 Hz, H-5B), 3.93 (m, 1H, H-2A), 3.81 (m, 4H, H-6aC, Me(OMP) 
or COOMe), 3.75 (s, 3H, Me(OMP) or COOMe), 3.74-3.66 (m, 3H, H-3D, H-6bC, H-
3B), 3.61 (dd, 1H, J2,3 = 10.6 Hz, J3,4 = 3.4 Hz, H-3C), 3.33 (m, 2H, H-5A, H-5C), 2.83-
2.50 (m, 8H, CH2(Lev)), 2.19, 2.18 (2s, 6H, CH3(Lev)), 1.97, 1.61 (2s, 6H, CH3(Ac)), 
1.06, 1.02 (2s, 18H, C(CH3)3);
 13C-NMR (100 MHz, CDCl3): δ 206.9, 206.3 (CO(Lev)), 
171.7, 171.5, 170.4, 170.3, 168.9, 168.8, 165.0 (CO(Lev), CO(Ac), CO(Bz), COOBn, 
COOMe), 158.1 (q, 2JC,F = 36.4 Hz, COCF3), 157.7 (q, 
2JC,F = 36.4 Hz, COCF3), 156.0, 
151.1, 137.8, 137.6, 134.7 (Ar-C), 133.4, 129.9, 129.7, 129.6, 129.4, 129.1, 128.7, 
128.5, 128.1, 127.9, 127.6, 120.3 (Ar-C, Ar-CH), 116.0 (q, 1JC,F = 286.3 Hz, COCF3), 
115.5 (q, 1JC,F = 287.9 Hz, COCF3), 114.6 (Ar-CH), 100.4 (C-1B), 100.3 (C-1D), 99.7 
(C-1C), 99.3 (C-1A), 80.1 (C-3B), 78.0 (C-4B), 76.4 (C-3C), 75.5 (C-3A), 75.1 
(CH2(Bn)), 74.3 (C-5B), 73.3 (C-4A), 73.0 (C-3D), 72.6 (CH2(Bn)), 72.4 (C-2B), 71.4, 
71.1 (C-5A, C-5C), 68.5, 68.4 (CH2(Bn), C-4D), 67.8 (C-4C), 67.5 (C-2D), 67.0 (C-5D, 
C-6A), 61.0 (C-6C), 55.7 (COOMe or Me(OMP)), 54.2 (C-2A), 53.5 (C-2C), 52.6 
(COOMe or Me(OMP)), 37.9, 37.7 (CH2(Lev)), 29.9 (CH3(Lev)), 28.0, 27.7, 27.6 
(CH2(Lev), C(CH3)3), 23.4 (C(CH3)3), 20.8, 20.7, 20.1 (C(CH3)3, CH3(Ac)); HR MS: 






4,6-di-O-sulfo-β-D-galactopyranoside (30): An excess of (HF)n·Py (56 µL, 2.1 mmol) 
was added at 0°C under an argon atmosphere to a solution of 26 (20 mg, 0.011 mmol) in 
dry THF (1.0 mL). After 24 h at 0ºC, the mixture was diluted with CH2Cl2 and washed 
with H2O and saturated NaHCO3 solution until neutral pH. The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo to give 27. TLC (toluene/EtOAc 1:2) Rf 
0.14; [α] 20D  –4º (c 0.9, CHCl3); 
1H-NMR (400 MHz, CDCl3): δ 7.85 (d, 2H, Ar), 7.56 (t, 
1H, Ar), 7.48-7.23 (m, 12H, Ar), 7.13 (d, 1H, J2,NH = 8.2 Hz, NH), 7.06 (m, 5H, Ar), 
7.00 (d, 1H, J2,NH = 6.4 Hz, NH), 6.86 (m, 2H, Ar), 6.74 (m, 2H, Ar), 5.36 (d, 1H, J1,2 = 
8.4 Hz, H-1A), 5.25 (q, 2H, CH2(Bn)), 5.23 (m, 2H, H-2B, H-4D), 5.16 (bs, 1H, H-4C), 
4.98 (bs, 1H, H-1D), 4.93 (bs, 1H, H-5D), 4.80 (m, 3H, H-1B, H-2D, CH2(Bn)), 4.63 (q, 
2H, CH2(Bn)), 4.54 (m, 2H, H-1C, CH2(Bn)), 4.46 (bd, 1H, J2,3 = 10.6 Hz, H-3A), 4.20 
(t, 1H, J3,4 = J4,5 = 8.2 Hz, H-4B), 4.13 (bs, 1H, H-4A), 4.08 (bd, 1H, J4,5 = 8.8 Hz, H-
5B), 4.02 (m, 1H, H-2C), 3.89 (m, 1H, H-6aC), 3.83-3.71 (m, 12H, H-2A, H-6aA, 
H-6bA, H-3B, H-3C, H-3D, Me(OMP), COOMe), 3.63 (m, 2H, H-6bC, H-5C), 3.54 (bt, 
1H, H-5A), 2.82-2.49 (m, 8H, CH2(Lev)), 2.18 (s, 6H, CH3(Lev)), 1.90, 1.64 (2s, 6H, 
CH3(Ac)); 
13C-NMR (100 MHz, CDCl3): δ 207.1, 206.4 (CO(Lev)), 171.7, 171.5, 
170.5, 170.3, 168.9, 168.8, 165.2 (CO(Lev), CO(Ac), CO(Bz), COOBn, COOMe), 
158.0 (bq, 2JC,F = 37.4 Hz, 2xCOCF3), 155.8, 151.1, 137.8, 137.6, 134.8 (Ar-C), 133.6, 
129.9, 129.5, 129.3, 129.2, 128.9, 128.5, 128.2, 128.1, 127.9, 127.8, 127.7, 119.0 (Ar-C, 
Ar-CH), 116.0 (q, 1JC,F = 287.6 Hz, COCF3), 115.2 (q, 
1JC,F = 287.6 Hz, COCF3), 114.7 
(Ar-CH), 101.6 (C-1B), 100.5 (C-1D), 100.1 (C-1C), 98.7 (C-1A), 80.0 (C-3B), 78.5 
(C-3A), 77.8 (C-4B), 76.5 (C-3C), 75.1 (CH2(Bn)), 74.7 (C-5C), 74.3 (C-5B), 73.3 (C-
3D), 72.9 (CH2(Bn)), 72.6 (C-2B), 71.3 (C-5A), 69.4 (C-4D), 68.7 (CH2(Bn)), 68.6 
(C-4A), 68.1 (C-4C), 68.0 (C-2D), 67.3 (C-5D), 62.8 (C-6C), 61.4 (C-6A), 55.8 
(COOMe or Me(OMP)), 54.7 (C-2A), 53.9 (C-2C), 52.8 (COOMe or Me(OMP)), 37.9, 
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37.8 (CH2(Lev)), 29.9, 29.8 (CH3(Lev)), 28.0, 27.7 (CH2(Lev)), 20.6, 20.2 (CH3(Ac)); 
HR MS: m/z: calcd for C78H84F6N2O31Na: 1681.4860; found: 1681.4868 [M+Na]
+.  
H2O2 (30%, 0.44 mL) and an aqueous solution of LiOH (0.7 M, 0.27 mL) were added at 
-5ºC to a solution of 27 (11.1 µmol) in THF (1.5 mL). After stirring for 20 h at room 
temperature, MeOH (1.5 mL) and an aqueous solution of NaOH (4 M, 0.28 mL) were 
added. After stirring for 6 d at room temperature, the reaction mixture was neutralized 
with Amberlite IR-120 (H+) resin, filtered, and concentrated to give 28. ESI MS: m/z: 
calcd for C45H57N2O22: 977.3; found: 977.2 [M+H]
- 
Triethylamine (0.4 mL of a 0.36 M solution in dry MeOH) and acetic anhydride (21 µL, 
0.22 mmol) were added to a cooled (0ºC) solution of 28 (11.1 µmol) in dry MeOH (2.5 
mL). After stirring for 2 h at room temperature, triethylamine (0.3 mL) was added and 
the mixture was concentrated to dryness. The residue was purified by Sephadex LH-20 
chromatography (CH2Cl2-MeOH 1:1) to give 29 as triethylammonium salt. The sodium 
salt of 29 was obtained by treatment with Amberlite IR-120 H+ resin in MeOH (pH ~ 
3), followed by filtration, treatment with 0.1 M NaOH (pH ~ 7) and concentration.  
1H-NMR (500 MHz, MeOD, data for sodium salt): δ 7.58 (d, 2H, Ar), 7.45 (d, 2H, Ar), 
7.34-7.21 (m, 6H, Ar), 6.98 (m, 2H, Ar), 6.82 (m, 2H, Ar), 5.06 (d, 1H, CH2(Bn)), 4.93 
(d, 1H, J1,2 = 8.4 Hz, H-1A), 4.89 (d, 1H, J1,2 = 4.4 Hz, H-1D), 4.77 (q, 2H, CH2(Bn)), 
4.73 (d, 1H, CH2(Bn)), 4.62 (d, 1H, J1,2 = 8.5 Hz, H-1C), 4.43 (m, 1H, H-1B), 4.41 (d, 
1H, J4,5 = 3.7 Hz, H-5D), 4.27 (dd, 1H, J2,3 = 10.6 Hz, H-2A), 4.23 (dd, 1H, J2,3 = 10.4 
Hz, H-2C), 4.13 (d, 1H, J3,4 = 2.7 Hz, H-4A), 4.05 (d, 1H, J3,4 = 2.7 Hz, H-4C), 3.99-
3.95 (m, 2H, H-4B, H-4D), 3.84-3.69 (m, 9H, H-6aA, H-6aC, H-6bA or H-6bC, H-3A 
(3.80), Me(OMP) (3.74), H-5B (3.72), H-3C (3.71)), 3.65-3.58 (m, 3H, H-6bA or 
H-6bC, H-2D, H-5A or H-5C), 3.55 (t, 1H, J2,3 = J3,4 = 5.9 Hz, H-3D), 3.52 (m, 1H, H-
5A or H-5C), 3.47-3.44 (m, 2H, H-2B, H-3B), 2.05, 1.99 (2s, 6H, NHAc); 13C-NMR 
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(125 MHz, MeOD) (selected data from HSQC experiment): δ 129.9-128.4, 118.9, 115.1 
(Ar-CH), 105.6 (C-1B), 103.9 (C-1D), 102.1 (C-1A), 101.3 (C-1C), 83.7 (C-3B), 81.8 
(C-3C), 81.7 (C-3A), 80.3 (C-3D), 78.9 (C-4B), 77.7 (C-5B), 77.2, 76.5 (C-5A, C-5C), 
76.4 (CH2(Bn)), 74.0 (C-2B), 73.6 (CH2(Bn)), 71.7 (C-5D), 71.2 (C-4D), 70.6 (C-2D), 
69.4 (C-4C), 68.8 (C-4A), 62.7, 62.3 (C-6A, C-6C), 55.7 (Me(OMP)), 52.7 (C-2C), 
52.6 (C-2A), 23.1, 22.8 (NAc); ESI MS: m/z: calcd for C49H61N2O24: 1061.4; found: 
1061.2 [M+H]-. 
Compound 29 (11.1 µmol) and sulfur trioxide–trimethylamine complex (54 mg, 0.39 
mmol) were dissolved in dry DMF (1.5 mL) and heated at 100ºC for 2 h using 
microwave radiation (20 W average power). The reaction vessel was cooled and Et3N 
(150 µL) and MeOH (1 mL) were added. The solution was layered on the top of a 
Sephadex LH-20 chromatography column which was eluted with MeOH to obtain 30 as 
triethylammonium salt. The residue was converted into the sodium salt by elution from 
a column of Dowex 50WX4-Na+ with MeOH-H2O 9:1 (6.9 mg, 34% from 26; 4 steps, 
76% average yield per step). Due to extensive overlap of 1H-NMR signals of the sodium 
salt at 25ºC, 30 was characterized as calcium salt at 40ºC. The calcium salt of 30 was 
obtained by adding a 0.9 M solution of CaCl2 in D2O. 
1H-NMR (500 MHz, D2O, 40ºC, 
data for calcium salt): δ 7.73 (d, 2H, Ar), 7.63-7.46 (m, 8H, Ar), 7.23 (m, 2H, Ar), 7.11 
(m, 2H, Ar), 5.44 (bs, 1H, H-1D), 5.37 (d, 1H, J1,2 = 8.6 Hz, H-1A), 5.30 (bs, 1H, 
H-5D), 5.11 (bd, 1H, H-4A), 5.02 (bs, 1H, H-4C), 4.98 (q, 2H, CH2(Bn)), 4.91-4.81 (m, 
5H, H-1B (4.90), H-4D (4.89), CH2(Bn), H-1C (4.84)), 4.52 (t, 1H, J1,2 = J2,3 = 7.5 Hz, 
H-2B), 4.47 (dd, 1H, J5,6a = 2.6 Hz, J6a,6b = 11.3 Hz, H-6aA or H-6aC), 4.43-4.19 (m, 
10H, H-2D (4.43), H-6aA or H-6aC, H-3A (4.39), H-3D (4.36), H-6bA, H-6bC, H-5A 
or H-5C (4.33), H-4B (4.29), H-2C (4.24), H-2A (4.22)), 4.14 (m, 1H, H-3C), 4.10 (bt, 
1H, H-5A or H-5C), 3.99-3.94 (m, 5H, H-3B (3.98), H-5B (3.97), Me(OMP) (3.94)), 
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2.21 (s, 6H, NHAc); 13C-NMR (125 MHz, D2O, 40ºC) (selected data from HSQC 
experiment): δ 129.6-128.5, 118.6, 115.2 (Ar-CH), 102.2 (C-1B), 101.5 (C-1D), 100.6 
(C-1A), 100.4 (C-1C), 80.2 (C-3B), 79.6 (C-3C), 79.1 (C-2B), 77.5 (C-4B), 77.4 (C-
5B), 76.7 (C-3A), 75.7 (C-4A), 75.3 (C-4C), 74.2 (CH2(Bn)), 72.8 (C-5A or C-5C), 
72.6 (C-4D), 72.4 (C-5A or C-5C), 71.9 (C-3D), 71.4 (CH2(Bn)), 71.2 (C-2D), 68.2 (C-
5D), 67.8, 67.4 (C-6A, C-6C), 56.0 (Me(OMP)), 52.4 (C-2A), 52.2 (C-2C), 22.8 (NAc); 
ESI MS: m/z: calcd for C49H55N2O45S7Na5: 865.0; found: 865.0 [M+5Na+2H]
2-; HR 





galactopyranoside (1): A solution of 30 (4.9 mg, 2.7 µmol, sodium salt) in H2O/MeOH 
(4.5 mL/0.5 mL) was hydrogenated (1.5 atm) in the presence of Pd(OH)2. After 22 h, 
the suspension was filtered over Celite and concentrated. The residue was purified by 
Sephadex G-25 chromatography (H2O/MeOH 9:1) to give 1 as sodium salt after 
lyophilisation (3.6 mg, 82%; 28% from 26, 5 steps, 78% average yield per step). 
1H-NMR (500 MHz, D2O): δ 7.10 (d, 2H, Ar), 6.98 (d, 2H, Ar), 5.29 (bs, 1H, H-1D), 
5.22 (d, 1H, J1,2 = 8.4 Hz, H-1A), 4.98 (bs, 1H, H-5D), 4.95 (bs, 1H, H-4A), 4.76 (m, 
1H, H-4C), 4.72 (m, 1H, H-1C), 4.70 (d, 1H, J1,2 = 7.7 Hz, H-1B), 4.66 (bs, 1H, H-4D), 
4.43 (m, 1H, H-3D), 4.35 (bd, 1H, H-6aA or H-6aC), 4.31-4.20 (m, 7H, H-6aA or H-
6aC, H-3A (4.27), H-6bA, H-6bC, H-5A or H-5C (4.23), H-2B (4.22), H-2D (4.20)), 
4.14-4.07 (m, 4H, H-2A, H-2C, H-5A or H-5C, H-3C), 3.93 (t, 1H, J3,4 = J4,5 = 9.1 Hz, 
H-4B), 3.82-3.81 (m, 4H, Me(OMP), H-3B), 3.73 (d, 1H, J4,5 = 9.4 Hz, H-5B), 2.11, 
2.05 (2s, 6H, NHAc); 13C-NMR (125 MHz, D2O) (selected data from HSQC 
experiment): δ 118.8, 115.5 (Ar-CH), 103.1 (C-1B), 101.3 (C-1C), 101.0 (C-1A), 100.7 
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(C-1D), 81.0 (C-4B), 80.1 (C-2B), 77.0 (C-5B, C-3A), 76.6 (C-3C), 76.4 (C-4A), 76.1 
(C-4C), 74.8 (C-4D), 73.9 (C-3B), 73.2, 72.7 (C-5A, C-5C), 72.6 (C-2D), 68.5, 67.9 (C-
6A, C-6C), 67.0 (C-5D), 66.5 (C-3D), 56.2 (Me(OMP)), 52.8, 52.4 (C-2A, C-2C), 23.2, 
22.8 (NAc); ESI MS: m/z: calcd for C35H43N2O45S7Na5: 774.9; found: 774.8 
[M+5Na+2H]2-; HR MS: m/z: calcd for C35H48N2O45S7: 719.9792; found: 719.9786 
[M+7H]2-. 
Fluorescence polarization assays 
Fluorescence polarization measurements were performed in 384-well microplates (black 
polystyrene, non-treated, Corning) using a TRIAD multimode reader (Dynex). 
Fluorescent probes 36-40, recombinant human FGF-2 (Peprotech), and inhibitors were 
dissolved in PBS buffer (10 mM, pH 7.4). For direct binding, 20 µL of a fluorescent 
probe solution (20 nM) were transferred to each well. Then 20 µL of FGF-2 solution 
(concentration ranging from 1.45 µM to 23 nM) were added and the microplate was 
shaked in the dark for 5 min, before reading. The total sample volume in each well was 
40 µL. Control wells contained 20 µL of the fluorescent probe solution and 20 µL of 
PBS buffer. Blank wells contained 20 µL of FGF-2 solution and 20 µL of PBS buffer 
and their measurements were substracted from all values. All samples were performed 
in replicates of three. For inhibition assay, 10 µL of probe and 20 µL of protein at fixed 
concentration (40 nM and 205 nM, respectively) were mixed with 10 µL of inhibitor 
solution (100 µM). The total sample volume in each well was again 40 µL. After 
stirring for 5 min in the dark, fluorescence polarization was recorded. Two control wells 
containing no inhibitor and probe only (no FGF-2) were included in the study. For the 
determination of IC50 value, wells containing probe and FGF-2 at fixed concentration, 
as described above, were incubated with 6 different concentrations of inhibitor, ranging 
from 0.025 µM to 100 µM. Average polarization values of six replicate wells were 
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plotted against the logarithm of inhibitor concentration, and the curve was fitted to the 
simplified formula corresponding to a one-site competitive interaction. All the 
experiments were repeated at least twice.    
Occasionally, we found loss of FGF-2 activity when working with low concentrated 
aliquots in PBS buffer. For this reason, all measurements were alternatively done in 








Figure 1. Disaccharide repeating units of chondroitin (left) and dermatan (right) sulfate 
with potential sites of sulfation indicated. 
 




Scheme 2. a) TEMPO, Bu4NBr, KBr, Ca(ClO)2, NaHCO3, CH2Cl2/H2O, 0ºC; BnBr, 
DMF, Bu4NI, 60ºC, 56%; b) LevOH, DCC, DMAP, CH2Cl2, 81%; c) CAN, 
toluene/CH3CN/H2O, 60%; d) Cl3CCN, K2CO3, CH2Cl2, 96%; e) Lev2O, Py/CH2Cl2, 
DMAP, 98%; f) (HF)n·Py, THF, 0ºC, 77%; g) Cl3CCN, K2CO3, CH2Cl2, 95%. 
 
 
Scheme 3. a) 4-methoxyphenol,  TMSOTf, CH2Cl2, 0ºC, 42% + 40% starting material; 
b) NaOMe, MeOH, quantitative; c) PhCH(OMe)2, p-TsOH, CH3CN, 87%; d) 
tBu2Si(OTf)2, Py, 89%; e) BnNH2, THF; TDSCl, imidazole, CH2Cl2, 51%; f) NaOMe, 
MeOH; PhCH(OMe)2, p-TsOH, CH3CN/DMF; g) NaOMe, MeOH; (ClAc)2O, collidine, 




Scheme 4. a) TMSOTf, CH2Cl2, 0ºC, 91%; b) NH2NH2·H2O, Py/AcOH, CH2Cl2, 84%; 
c) TMSOTf, CH2Cl2, 0ºC, 79%. 
 
Scheme 5. a) (HF)n·Py, THF, 0ºC, 97%; b) Ac2O, Py, DMAP, 89%; c) CAN, 
toluene/CH3CN/H2O, 0ºC, 76%; d) Cl3CCN, DBU, CH2Cl2, 84%; e) 25, TMSOTf, 






Scheme 6. a) (HF)n·Py, THF, 0ºC; b) LiOH, H2O2, THF; NaOH, MeOH; c) Ac2O, 
MeOH, Et3N; d) SO3·Me3N, DMF, 100ºC, MW, 34% from 26, 4 steps, 76% average 
yield per step; e) H2, Pd(OH)2, H2O/MeOH, 82%. 
 
 
Table 1. 1H-NMR chemical shifts for sulfated positions of compounds 30 and 1 and the 
corresponding non-sulfated positions of 29.  
Compound H-4A H-6A H-2B H-4C H-6C H-2D H-4D 
29a 4.13 3.84-3.58 3.47-3.44 4.05 3.84-3.58 3.65-3.58 3.99-3.95 
30b 5.11 4.47-4.19 4.52 5.02 4.47-4.19 4.43 4.89 
1c 4.95 4.35-4.20 4.22 4.76 4.35-4.20 4.20 4.66 
a sodium salt, in MeOD; bcalcium salt, in D2O; 
csodium salt, in D2O 
Table 2. 13C-NMR chemical shifts for sulfated positions of compounds 30 and 1 and the 
corresponding non-sulfated positions of 29. 
Compound C-4A C-6A C-2B C-4C C-6C C-2D C-4D 
29a 68.8 62.7 or 62.3 74.0 69.4 62.7 or 62.3 70.6 71.2 
30b 75.7 67.8 or 67.4 79.1 75.3 67.8 or 67.4 71.2 72.6 
1c 76.4 68.5 or 67.9 80.1 76.1 68.5 or 67.9 72.6 74.8 
a sodium salt, in MeOD; bcalcium salt, in D2O; 




Scheme 7. a) Fluorescein hydrazide, DMSO/phosphate buffer pH 5.5 (1:1), 30ºC, 91% 




























Figure 2. Fluorescence polarization values (right, in grey) from wells containing 
fluorescent GAG oligosaccharides 36-40 (10 nM) and FGF-2 (97 nM) are compared 
with the values obtained in the absence of the protein (left, in white). For each 
oligosaccharide, polarization values are the average of three replicate wells and the error 






Figure 3. Schematic representation of the competition assay. The displacement of a 
fluorescent sugar from a protein receptor by an active competitor results in a decrease of 
the polarization value. Thus, the binding affinities of non-fluorescent compounds can be 
estimated.     
 
Figure 4. Competition assay to analyse the inhibitory potency of a collection of 
synthetic oligosaccharides (1, 30, 41-46). The graphic presents the polarization values 
obtained from wells containing 25 µM inhibitor, 103 nM FGF-2, and 10 nM fluorescent 
38. Control wells (in white) correspond to samples with probe only (left) and no 
inhibitor (right) and indicate the expected values for 100% and 0% inhibition, 
respectively. All the measurements are the average of three replicate wells and the error 
























Figure 5. Inhibition curve showing the ability of tetrasacharide 1, at different 
concentrations (from 0.025 µM to 100 µM), to inhibit the interaction between FGF-2 
(103 nM) and probe 38 (10 nM). The concentration required to inhibit 50% binding 
(IC50 value) was calculated from data analysis (see main text). Control wells, with no 
inhibitor and no protein, were included in the fitting. All the polarization values are the 
average of six replicate wells.  
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